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Abstract 
 
1 Abstract 
 
Triggering of dendritic cell (DC) migration into tumor tissue and subsequent 
expansion of dendritic cells may be useful to generate anti-tumor immune response by 
adenoviral gene transfer employing cytokines and growth factors for dendritic cell 
migration and expansion to improve cross-presentation of tumor antigens during 
oncolytic virotherapy.  
Appropriate syngenic mouse models were established for lung carcinoma cells 
CMT64 and KLN205. In vitro replication assay showed that CMT64 and KLN205 are 
permissive for replication of the oncolytic telomerase-dependent adenovirus hTERT-
Ad. Further in vivo replication was studied using replication defective adenovirus 
expressing Luciferase gene in combination of telomerase dependent adenovirus. 
We used adenoviral expression of Macrophage Inflammatory Protein 1α (MIP-1α) to 
recruit DCs into hTERT-Ad infected tumors and Ad-Flt3L to expand DCs within the 
tumor nodules during virotherapy. 
Compared with virotherapy alone or virotherapy with expression of a single CC 
chemokine, expression of both MIP1α and Flt3L during virotherapy significantly 
increases infiltration of DCs and T cells, as shown by histochemistry. Interferon-γ, 
and CTL assay showed that the combination of cytokines improve cross-presentation 
of tumor antigens and induces an anti-tumor immune response during virotherapy. 
Combination of viroimmunotherapy and DC vaccination showed nearly complete 
regression of the subcutaneous tumors and very strong inhibition of established lung 
metastasis. 
In conclusion mobilizing of DCs to tumors during virotherapy improves cross-
presentation of tumor antigens and induced anti-tumor immune response, which 
facilitates an effective viroimmunotherapy of established solid tumors in vivo. The 
results show high efficacy of the viroimmunotherapy, which may be considered as 
safe even, when translated to human cancer therapy.  
Key words: virotherapy, immune answer, dendritic cell migration 
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Zusammenfassung 
 
2 Zusammenfassung 
 
Die Stimulation der Wanderung und die nachfolgende Expansion von dendritischen 
Zellen in Tumore, die durch tumor-spezifisch replizierende Viren infiziert sind, 
könnte ein attraktiver Ansatz sein, um die Tumorimmunantwort durch 
Kreuzpräsentation von Tumorantigenen im Rahmen einer Virotherapie zu verstärken.  
Es wurden geeignete syngene Mausmodelle für diese immunologischen 
Untersuchungen mit den Tumorzelllinien CMT64 und KLN205 etabliert. In vitro 
Replikations-Assays zeigten, dass sowohl in KLN 205 als auch in CMT64 das 
humane telomerase-abhängige Adenovirus hTert-Ad repliziert. Weitere in vivo-
Untersuchungen durch die Generierung und Verwendung eines Lufizerase-
exprimierenden Adenovirus bestätigten die virale Replikation von hTert-Ad in den 
entsprechenden subkutanen Tumoren.  
Um die Migration und Expansion der dendritischen Zellen in den Tumoren im 
Rahmen der Virotherapie zu induzieren, wurden zwei nicht replikative Adenoviren 
kloniert, die das Macophage Inflammatory Protein 1α (MIP-1α) und Flt3L 
exprimieren.  
Im Vergleich zur Virotherapie alleine, oder zur Virotherapie mit einem einzelnen CC 
Chemokine, resultierte die gemeinsame Expression von MIP-1α und Flt3L in einer 
signifikant gesteigerten Infiltration der Tumoren mit dendritischen Zellen und T-
Zellen. IFN-γ-ELISpots und CTL-Assays zeigten, dass die Kombination von MIP-1α 
und Flt3L die Kreuzpräsentation von tumorspezifischen Antigenen stark stimuliert 
und eine starke antitumorale Immunantwort auslöst. Durch die weitere Kombination 
der MIP-1α /Flt3L-Virotherapie mit einer dendritischen Zell-Impfung, konnten 
nahezu komplette Remissionen der subkutanen Tumore und eine sehr starke 
Hemmung von Lungenmetastasen erzielt werden, sodass über 50% der Tiere geheilt 
werden konnten. 
Zusammenfassend zeigt diese Arbeit, dass die Wanderung und Expansion von 
dendritischen Zellen in Tumoren, die durch tumorspezifische Viren infiziert wurden,  
die Kreuzpräsentation von tumorspezifischen Antigenen verstärkt und hierdurch eine 
starke tumorspezifische Immunantwort auslöst. Dies ermöglicht eine effektive 
Viroimmuntherapie von etablierten soliden Tumoren und ihren Metastasen.  Die 
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Ergebnisse dieser Arbeit zeigen die hohe Effektivität der Viroimmuntherapie, die 
hoffentlich als sichere Tumortherapie Eingang in die klinische Praxis finden wird.  
Key words: Virotherapie, immune antwort, dendritische zell migration  
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3 Introduction 
 
3.1 Cancer 
 
Cancer is a group of over 100 diseases characterized by uncontrolled growth of 
transformed cells. Cancer is classified according to the cell types and organs from 
which they originate. Carcinoma is the most common form of cancer that arises in the 
epithelium, the layers of cells covering body surfaces or lining internal organs and 
various glands. In this thesis, two lung cancers are discussed, namely small lung 
carcinoma cell line (CMT 64) and squamous cell carcinoma (KNL205). 
 
Cancer is a world wide health problem which was responsible for the death of 
millions of people every year. Even though our knowledge of molecular mechanisms, 
diagnostic methods and traditional treatments of cancer have all improved during the 
last decades, most cancer types still have a poor prognosis and evoke a high mortality, 
this being especially the case with metastatic types. Thus, more efficient approaches 
and improved therapeutic strategies are needed for the treatment of cancer.  
The first clinical gene therapy trial was carried out in the early 1990s. From that 
beginning, gene therapy has become a widely studied concept for treatment of various 
diseases. Even though gene therapy was initially thought to be more suitable for the 
treatment of inherited monogenic diseases, gene therapy has been increasingly utilized 
in the treatment of acquired and complex diseases such as cancer. In fact, by the year 
2004, the majority of clinical gene therapy trials (66%) have focused on cancer 
diseases.  
 
Even though several approaches have been successfully developed to improve the 
gene transfer efficiency, one major obstacle in cancer gene therapy is still insufficient 
transduction of the gene and consequently a poor therapeutic effect. There are several 
possibilities that can be utilized to circumvent this problem. First, new alternative 
viral vectors can be explored to find optimal gene transfer vehicle for each purpose. 
Secondly, viral vectors can be re-targeted to cancer cells, which simultaneously 
  4  
 
 
 
Introduction 
 
enhance gene transfer rates in tumors and diminish undesired side effects in healthy 
tissue. In addition, it is possible to exploit viral replication per se to destroy cancer 
cells by transcription regulation. To avoid side effects and to increase the safety of 
these oncolytic agents, replication can be restricted to tumor cells by partially deleting 
the viral genome or by using tissue specific promoters to drive the viral genes 
responsible for replication. 
 
3.2 Cancer Associated Genes 
 
3.2.1 Overview 
Three major gene types have been shown to be closely related to tumorigenesis: 
proto-oncogenes, tumor-suppressor genes and DNA mismatch repair genes. Since 
cancer is a group of neoplastic diseases involving multiple steps and genetic events, 
tumor development usually requires alterations in a number of cancer-associated 
genes. A transformed phenotype when combined with a metastatic capability typically 
involves both oncogene activation and tumor suppressor gene loss or inactivation 
(Bast et al., 2000). Furthermore, it is noteworthy that the same genes causing genetic 
predisposition to cancer are most often associated and involved in sporadic forms of 
carcinogenesis (Knudson et al, 1991). 
 
3.2.2 Proto-oncogenes 
The proto-oncogenes encode proteins that have a crucial role in cell signaling 
pathways. The proto-oncogenic products (including various growth factors and their 
receptors, signal transducers and transcription factors) control the growth and 
differentiation of normal cells (Aaronson, 1991; Bast et al., 2000). These proto-
oncogenes can be activated to carcinogenic oncogenes through mutation, gene 
amplification or chromosomal rearrangement resulting in an altered proto-oncogene 
structure or an increased proto-oncogene expression (Bast et al., 2000). Thus 
activation of oncogenes offers a growth advantages to the cell and eventually normal 
cells become transformed.  
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3.2.3 Tumor suppressor genes  
Tumor suppressor genes can prevent cell growth by several pathways either by 
blocking the cell cycle or by promoting cell cycle arrest and apoptosis (McCormick et 
al, 2001). In cancer cells, these genes are inactivated and block the control of normal 
cell cycle and thus increase the probability of tumor formation (Knudson et al, 2001).  
 
3.2.4 DNA mismatch repair (MMR) genes 
The DNA mismatch repair (MMR) system is one of the three cellular mechanisms 
involved in DNA repair (Charames and Bapat, 2003). MMR proteins recognize and 
eliminate potential misincorporated nucleotides on the newly synthesized DNA strand 
during DNA replication (Fedier and Fink, 2004). Hence, MMR machinery is a crucial 
mechanism for maintaining genome integrity during cell proliferation. Mutations in 
genes encoding MMR proteins attenuate or inactivate the DNA repair machinery and 
thus interfere with genetic stability and increase the incidence of further mutations 
during the DNA synthesis (Fedier and Fink, 2004). This increased mutation frequency 
thus augments the susceptibility to undergo cellular transformations and tumor 
formation (Eshleman and Markowitz, 1996). Mutated MMR proteins have been 
identified and associated with various cancer types including hereditary nonpolyposis 
colon cancer (Bronner et al., 1994; Fishel et al., 1993), breast (Balogh et al., 2003) 
and bladder cancer as well as gliomas. In addition, tumor cells with a defective MMR 
system have been shown to display reduced sensitivity to the cytotoxic, DNA 
damaging chemotherapeutic drugs such as cisplatin (Brown et al., 1997) and 
doxorubicin (adriamycin). 
 
3.3 The Immune System 
 
The immune system is an organization of cells and molecules that have evolved in 
order to protect an organism from foreign pathogens and possibly against altered self-
cells that may lead to cancer. The immune system can be divided into two parts, the 
innate (natural) and adaptive (acquired) immune systems. In reality, a cross talk 
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between the innate and adaptive immune response is needed in order to eliminate 
many pathogens. 
3.3.1 Innate immunity 
The very first lines of defense against foreign pathogens are physical barriers to the 
outer world such as mucosal epithelial surfaces that contain lysozymes and other 
secretary factors that prevent pathogen growth. Other molecular components include 
the complement system, cytokines and acute phase proteins. Cells of the innate 
immune system include phagocytic cells (neutrophils, monocytes, macrophages and 
DCs), cells that release inflammatory mediators (basophils, eosinophils and mast 
cells), and natural killer (NK) cells, all with pre-existing receptors for pathogens. In 
mammalian cells, TLRs are important PRRs responsible for a large proportion of the 
innate immune recognition of pathogens (Akira S, 2004).There is strong evidence that 
these TLRs are responsible for sensing the PAMPs or providing the "danger signal" 
for activation of the adaptive immune system (Guermonprez P, 2002). The innate 
system protects us but may only delay and not eliminate certain pathogens until the 
adaptive immune system becomes activated. 
 
3.3.2 Adaptive immunity 
Adaptive immunity is unique for vertebrates. The adaptive immune system mounts its 
response during an infection and is therefore slower, but in contrast to innate 
immunity it leads to immunologic memory. DCs are the key activators that link innate 
and adaptive immunity. The adaptive immune response consists of a humoral and a 
cellular response. Humoral immunity is mediated by B lymphocytes and their secreted 
products, namely antibodies. Antibodies are produced in response to antigens which 
often derive from extracellular pathogens such as bacteria and virus. Cell-mediated 
immunity involves macrophage and NK cell activation, the production of antigen-
specific T cells and the release of various cytokines in response to antigens. Cell-
mediated immunity is primarily a response to intracellular pathogens such as viruses. 
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3.3.3 Antigen Processing and Presentation 
Antigens are macromolecules that elicit immune response in the body. Majority of 
antigens for T cells are proteins, and these must be fragmented and recognized in 
association with MHC products expressed on the surface of nucleated cells, not in 
soluble form. Antigen processing and presentation are processes that occur within a 
cell that result in fragmentation (proteolysis) of proteins, association of the fragments 
with MHC molecules, and expression of the peptide-MHC molecules at the cell 
surface where they can be recognized by the T cell receptor on a T cell. However, the 
path leading to the association of protein fragments with MHC molecules differs for 
class I and class II MHC. MHC class I molecules present degradation products 
derived from intracellular (endogenous) proteins in the cytosol. MHC class II 
molecules present fragments derived from extracellular (exogenous) proteins that are 
located in an intracellular compartment. 
 
3.4 Major Histocompatibility Complex (MHC)  
 
3.4.1 Self MHC Restriction  
In order for a T cell to recognize and respond to a foreign protein antigen, it must 
recognize the MHC on the presenting cell as self MHC. This is termed self MHC 
restriction. Helper T cells recognize antigen in context of class II self MHC. Cytotoxic 
T cells recognize antigen in context of class I self MHC. The process whereby T cells 
become restricted to recognizing self MHC molecules occurs in the thymus.  
 
3.4.2 Presentation by MHC I  
Professional antigen presenting cells process intracellular antigens, such viruses or 
virus infected cells are degraded by the proteasome and the resulting peptides are 
shuttled into endoplasmic reticulum (ER) by TAP proteins. These peptides are loaded 
onto MHC class I molecules and the complex is delivered to the cell surface, where it 
stimulates naïve CD8 T cells. 
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3.4.3 Presentation by MHC II  
In contrast to MHC class I, extracellular antigens are engulfed by phagosomes or 
endocytosis. Inside phagosome, the antigen derived peptides are loaded directly onto 
MHC class II molecules, which activate helper T cells. 
 
3.4.4 Cross-Presentation  
Conventional presentation of exogenous antigen in the context of MHC-I pathway 
refers as cross presentation (Figure 3.1). It is the fundamental mechanism of 
induction of anti tumor immune responses. 
 
Figure 3.1 Antigen Processing and Presentation. 
A. Exogenous antigen ingested via endocytosis/phagocytosis. Once in the 
phagosome these antigens degraded by several processing enzymes and the 
antigen is degraded into small peptides, which complexes with MHC class II 
molecules and transported to the membrane of antigen presenting cells. 
B A 
This figure obtained from Janis Kuby, Immunology, 6th edition 
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B. Endogenous antigen produced with in the cells, or viral infected cells is 
degraded with in the cytoplasm by proteasome into peptides, these peptide 
move ER via transporter associated for antigen presentation where they bind to 
MHC class I molecules. These MHC-peptide complexes move to Golgi 
complex then to the cell surface  
 
3.4.5 T cell priming by DCs 
Immature DCs are distributed throughout the body. They have receptors for 
chemokines such as macrophage inflammatory protein (MIP)-3α, MIP-1α and 
RANTES. They accumulate rapidly, within an hour, at the sites of antigen deposition. 
Immature DCs are very efficient in capturing antigens in the forms of apoptotic and 
necrotic cell fragments (Banchereau J, 2000). Upon antigen uptake, DCs mature, 
downregulate their antigen internalization capacity and upregulate the surface 
expression of the co-stimulatory molecules CD80 and CD86 (Lanzavecchia A et al, 
2000). They also upregulate expression of chemokine receptors CXCR4 and CCR7. 
The upregulation of CCR7 promotes responsiveness to the chemokines MIP-3β and 
6Ckine that initiate DC migration. 6Ckine helps to co-localize mature DCs and naive 
T cells in the T cell zone of secondary lymphoid organs, i.e. the spleen and the lymph 
nodes, and contributes to T cell activation. It has long been thought that apoptotic cell 
death is poorly immunogenic (tolerogenic), whereas necrotic cell death is 
immunogenic. This difference was thought to result from an intrinsic capacity of cells 
dying from non-apoptotic cell death to stimulate the immune response: for example, 
by stimulating local inflammatory responses and/or by triggering the maturation of 
DCs. It seems, however, that the classification of necrosis as immunogenic and 
apoptosis as tolerogenic is an oversimplification. It has recently been shown that the 
capacity of apoptotic cells to trigger an immune response depends on the inducer of 
apoptosis (Casares N et al, 2005), indicating that qualitative differences in the 
biochemical mechanisms of cellular apoptosis could lead to different immune 
response outcomes. 
 
T cell receptors (TCRs) present on T cells recognize antigens in the form of peptide 
fragments bound to major histocompatibility complex (MHC) molecules on the 
surface of DCs. There are two types of MHC, class I and class II, which stimulate 
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CD8+ and CD4+ T cells, respectively (Banchereau J, 2000). Endogenously expressed 
antigens are processed in the cytosol of the DC and peptides are presented in the 
context of MHC class I molecules to naïve CD8+ T cells. Exogenously expressed 
antigens taken up by DCs through endocytosis are processed and generally presented 
as peptides by MHC class II molecules to CD4+ Th cells (Banchereau J et al, 2000). 
However, DCs have evolved a unique cross-priming mechanism to transport 
extracellular antigens to the cytosol where they are degraded and loaded onto MHC 
class I molecules for presentation to CD8+ T cells. This is called cross-presentation. 
Moreover, one DC can prime up to ten T cells at the same time. Engagement of TCRs 
by MHC-peptide complexes on the surface of APCs provides the first activation 
signal to naïve T cells to become CTLs. Activated CTLs migrate to the site of 
inflammation and kill target cells via Fas ligand and/or perforin / granzyme mediated 
killing (Igney FH et al, 2002). 
 
3.5 Cancer Immunotherapy 
 
Cancer immunotherapy is the use of the immune system to reject cancer. The main 
principle is stimulating the host immune system to attack the malignant tumor cells 
that are responsible for the disease. This can be either through immunization of the 
host, in which case the hosts own immune system is trained to recognize tumor cells 
as targets to be destroyed, or through the administration of therapeutic drugs, in which 
case the hosts immune system is recruited to destroy tumor cells by the therapeutic 
drugs. An efficient way to activate an individual’s immune system is through 
infiltration of immune cells into inflammatory tissue in case of cancer, tumor tissue 
where the interaction among tumor cells, T and DCs would activate immune system 
specifically to tumor antigens. 
 
3.5.1 Adenoviral vectors 
Cancer immunotherapy based on the delivery of genes encoding TAAs to DCs or 
immunomodulatory molecules to tumor cells requires an efficient gene transfer 
method. The genes being transferred are included in vectors that are either of viral or 
non-viral origin to improve transduction efficiency of therapeutic gene delivery; the 
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resulting therapeutic gene expression can transduced efficiently in to the local 
damaged tissue and compensate low transduction efficiency, to enhance therapeutic 
applications and low toxicity. 
 
3.5.2 Adenoviral vectors for Transgene delivery 
In the recent years, adenoviruses have received considerable attention for use in gene 
therapy because of their large cloning capacity and ease of genetic manipulation and 
growth. In addition their ability to transduce a wide range of tissue type containing 
both dividing and non-dividing cells. The most commonly used recombinant 
adenoviral vectors are generated from human adenoviruses of serotypes 2 and 5 
(Volpers C et al, 2004). Adenovirus genome is a double-stranded linear DNA 
molecule that codes for early and late proteins (Goncalves MA et al, 2006). Early 
genes encode proteins involved in host cell cycle regulation, anti-apoptosis, immune 
system deviation and virus replication. Late genes encode structural viral proteins and 
proteins involved in virus assembly. First generation Ad vectors, replication defective 
by deletion of E1A have proven an inadequate for long term, stable transgene 
expression necessary for correction of most genetic diseases. This could be because of 
foreignness versus self transgenes, strong innate immunity and generation of anti-Ad 
cytotoxic T lymphocytes and anti-adenoviral antibodies. It is likely that poor 
performance of clinical studies is of several reasons. 
 
The first interaction of an adenoviral vector with the host cell occurs through binding 
of the virus fiber knob to the coxsackie adenovirus receptor (CAR). 
Thereafter, the RGD (Arg-Gly-Asp) motif on the adenoviral penton base interacts 
with αV integrins, which act as a co-receptor for viral endocytosis. The virus is 
internalized into the cell and escapes from the endosome, a step in which the fibers 
and penton bases detach from the virus capsid. The partly uncoated adenoviral capsid 
is translocated along microtubules toward the nucleus. The adenoviral capsid is 
uncoated and the adenovirus genome enters the nucleus through nucleopores. The 
adenoviral vector stays episomal and the gene of interest carried by the adenoviral 
vector is expressed. 
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Adenoviruses are airborne viruses and therefore the primary targets for infection are 
the respiratory, gastrointestinal, and urinary tracts, as well as the eye (Kojaoghlanian 
T et al, 2003) However, adenoviruses can infect all cell types expressing CAR and 
integrins. Therefore, adenoviral vectors can provide highly efficient delivery of 
therapeutic genes in most cell cultures. It is easy to produce high viral titers for in 
vitro and in vivo purpose. The major disadvantage of adenoviral vectors is 
immunogenic and most of us have already antibodies against adenoviruses. Virus 
neutralizing antibodies induced by adenoviral infections or upon adenoviral vector 
delivery are primarily directed against the adenoviral surface hexon protein 
(Kojaoghlanian T et al, 2003). Moreover, adenoviruses activate the innate immune 
system to produce proinflammatory cytokines that can initiate differentiation of 
immature DCs (Muruve DA et al, 2004). Systemic administration of high doses of 
adenoviral vectors into mice (Zhang Y, 2001) was shown to trigger the rapid release 
of IL-6, IL-12, and TNF-α and show accumulation of immune cells in lymphatic 
tissue. However, in oncolytic virotherapy of cancers, specifically when using 
conditionally replicating adenoviruses in cancer therapy, combination of 
immunotherapy setting would be an additional induction of the immune system by the 
adenoviral vectors expressing cytokine like co-stimulatory molecules or cytokine 
which enhance immune cell infiltration into local tissue could lead to a desired 
immunological effect against tumor specific antigen delivered by adenoviral 
replication. 
Theoretically, metastatic disease may only be treated by the systemic delivery of 
targeted gene vectors. However, for locally advanced prostate cancer (T3 and T4) 
there are several ways to deliver the vectors. Steiner MS et al compared three routes 
of administering adenoviral vectors in a canine model: intravenous, intra-arterial and 
intraprostatic injections (Steiner MS et al, 1999). This study provides direct support 
for the use of intratumoral prostatic injections of gene therapy vectors. Generally, 
when the vector is administered directly to the target tissue or organ, toxicity is dose-
dependent and confined to the injection site. Another way to overcome side effects is 
to use a tumor or tissue-specific promoter to control transgene expression, which is 
also known as transcriptional targeting. Here again we used tumor specific promoter 
(Figure 3.2), human telomerase reverse transcriptase, the catalytic subunit of 
telomerase which drives E1A protein of adenovirus replication (Wirth T et al, 2003).  
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3.6 Merging virotherapy and immunotherapy 
 
Several gene therapy approaches have been demonstrated to cancer cells, clinical 
trails that the early generation viral vectors have rather limited ability to completely 
eradicate advanced tumor masses. In order to improve the efficacy of virotherapy, 
combination of immunotherapy approaches might be useful to eradicate established 
cancer specifically when using tumor specific viral replication to enhance tumor 
antigen specific immune response. In the present study we used adenoviral vectors for 
cytokine gene (Replication deficient Ad vectors) delivery into tumor tissue, which are 
E1A and E3 genes deleted (except hTERT-Ad) and are replication-deficient (MIP-1α, 
Flt3L, LacZ, GFP and Luciferase Ad-viruses) viruses. The deletions create space for 
introducing foreign promoters and genes of interest (Robbins PD et al, 1998).  
3.6.1 MIP-1α (Macrophage Inflammatory Protein 1α) 
Macrophage inflammatory protein 1α (MIP-1α) is a member of the C-C subfamily of 
chemokines, a large super family of low-molecular weight, inducible proteins that 
exhibit a variety of proinflammatory activities in vitro including leukocyte 
chemotaxis. MIP-1α (CCL3) is of a particularly interesting chemokine, because in 
addition to its proinflammatory activities, it inhibits the proliferation of hematopoietic 
stem cells in vitro and in vivo. The MIP-1α null mice have no overt abnormalities of 
peripheral blood or bone marrow cells, indicating that MIP-1α is not necessary for 
normal hematopoiesis. However, the MIP-1α null mice have reduced inflammatory 
response to influenza virus and are resistant to coxsackievirus-induced myocarditis. 
These data demonstrate that MIP-1α is required for a normal inflammatory response 
to these viruses.  
MIP-1α is structurally and functionally related CC chemokine. MIP-1α participate in 
the host response to invading bacterial, viral, parasite and fungal pathogens by 
regulating the trafficking and activation state of selected subgroups of inflammatory 
cells e.g. macrophages, lymphocytes and NK cells. MIP-1α exerts effect on 
lymphocyte differentiation and in selectively attracting CD8+ lymphocytes. 
Additionally, MIP-1α has also been shown to be potent chemo attractant for T cells 
and dendritic cells (New JY et al, 2002). Mostly immature DCs infiltrated by CC and 
CXC chemokines such as MIP-1a, MIP-5, and RANTES (MC Dieu-Nosjean et al, 
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1999). 
 
3.6.2 Flt3 ligand 
The fms-like tyrosine kinase 3 (Flt3), also known as stem cell tyrosine kinase-1 or 
fetal liver tyrosine kinase-2 (Lyman SD et al, 1993; Rosnet O et al, 1991). Flt3 
(CD135) is expressed on multipotent HSC and progenitor cells, suggesting a critical 
role in stem cell development and differentiation (Rosnet O et al, 1996). Analysis of 
Flt3 knockout mice has shown that mainly primitive B cell progenitors are reduced. 
Yet, normal numbers of functional B- cells are present in periphery. Flt3- Ligand 
knockout mice on the other hand show an overt reduction of leukocyte counts in bone 
marrow, spleen, thymus as well as peripheral blood. In addition these animals also 
show reduced numbers of myeloid and lymphoid dendritic cells and are deficient in 
NK cells. Similar to the receptor knockout mice these animal show slightly reduced 
numbers of myeloid progenitors (McKenna HJ et al, 2000). Many animal studies 
shown that adenoviral expressing Flt3L enhances number of dendritic cells in vivo 
and enhances immune response to specific antigens (Wang H et al, 2005) Another 
study showed that immunogenicity of DNA vaccine can be enhanced with dendritic 
cell migration (Sumida SM et al, 2004). 
 
3.6.3 Telomerase-dependent conditionally replicating adenovirus (hTERT-Ad) 
Telomeres are essential elements at chromosome termini that preserve chromosomal 
integrity by preventing DNA degradation, end to end fusions, rearrangements and 
chromosome loss (Blasco MA et al, 1997; Lee HW et al, 1998; Rudolph KL et al, 
1999). Each cell replication is associated with the loss of 30-150 bps of telomeric 
DNA that can compensated by telomerase, an RNA-dependent DNA polymerase 
(Greider CW et al, 1996). Ectopic expression of hTERT, the catalytic subunit of 
telomerase, is capable to reconstitute telomerase activity in telomerase negative cells, 
indicating that hTERT is the major determinant of telomerase activity in mammalian 
cells (Weinrich SL et al, 1997; Vaziri H et al, 1998). 
Most of human somatic cells neither exhibit hTERT expression not telomerase 
activity, hence limited number of cell divisions because of the reduction in telomeres 
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to a critical length. In contrast to quiescent somatic cell, in highly proliferative cells, 
such as germ-line, HSC or transformed cancer cells, diverse molecular mechanisms 
are necessary to maintain telomere length.  Most of human cancer cells acquire 
immortality by expression of the hTERT. It has been shown that hTERT expression is 
regulated at the transcriptional level (Poole JC et al, 2001). Previous studies 
demonstrated that the hTERT promoter is inactive in normal cells but is activated 
during carcinogenesis, thereby providing a promising tool for tumor specific gene 
expression (Abdul Ghani R et al, 2000; Koga S et al, 2000). 
In the present study, an adenoviral vector (hTERT-Ad) was constructed by replicating 
the internal adenoviral E1a promoter by a 255bp hTERT promoter fragment (Wirth et 
al, 2003). This altered transcriptional control of E1A expression was restricted to 
telomerase positive tumor cells. 
 
 
 
Figure 3.2 Schematic diagram of construction of hTERT-Ad (Wirth T et al, Cancer 
Research, 2003) 
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Figure 3.3 To achieve transgene expression specifically in the tissue of 
interest it is possible to either change the homing of the virus 
(transductional retargeting) or to alter the expression profile of the 
transgene (transcriptional retargeting). 
 
In this study, we examined several potential approaches to improve oncolytic 
virotherapy. First, we explored the feasibility of replication of murine tumor cells 
using conditionally replicating adenoviral vectors (hTERT-Ad) in cancer gene therapy 
(Wirth et al, 2003) (Figure 3.2 and 3.3). In addition, we used cytokines expressing in 
adenoviral vectors to attract immune cells into inflamed tissue. Finally, we established 
an efficient method for generating immune responses against tumor specific antigens 
using conditionally replicative adenovirus in combination of immunotherapy and 
evaluated its oncolytic potency and immune response for cancer gene therapy in 
murine model. 
 
Non-target 
Transduction retargeting
Target cell 
Transcriptional retargeting  
Tumor specific promotoer
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4 Aims of the study 
 
The major goal of this work was to define a protocol for the cancer therapy using 
oncolytic virotherapy and immunotherapy in small lung carcinoma and squamous 
carcinoma tumors in murine model. 
 
1. Evaluation of replication of murine tumor cells with conditionally replicating 
human adenovirus serotype 5 in vitro and in vivo 
 
2. To develop new strategies to enhance virotherapy efficacy by 
immunotherapeutic approaches in cells with defective in transporters 
associated with antigen processing lung carcinoma cells by recruiting immune 
cells into tumors 
 
3. To determine whether modulation of immune responses with 
viroimmunotherapy and antigen pulsed dendritic cell vaccination can 
modulate immune responses to virus and tumor 
 
4. To investigate whether viroimmunotherapy and dendritic cell vaccination has 
any effect on distant lung metastasis for further translation of 
viroimmunotherapy to humans 
 
 
 
 
 
 
 
  18  
 
 
 
Material and Methods 
 
5 Material and methods 
 
5.1 Animals  
 
Female C57Bl/6 (B6, H2b) and DBA/2 mice (6-12 weeks old) were purchased from 
Charles River, Germany. The animals were housed in sterilized individually 
ventilated cages at the animal facility of the Medical School of Hannover (MHH) and 
received sterilized food and water. All manipulations were performed under aseptic 
conditions in a laminar-flow hood.  
Transgenic OT-I mice (OVA323-339–SIINFEKL specific H2b-restricted TCR-
transgenic mice on a C57/BL6 background) (1) were generously provided by Dr. 
Martin Sauer, MHH. All experiments were conducted under approved animal 
protocols of the state government of Lower Saxony, Germany. 
 
5.2 Cell lines 
 
CMT64, a C57/BL6 (H-2b) derived lung carcinoma cell line exhibits low expression 
of tumor-associated antigen presentation in the context of MHC class I antigens 
because of defects in the antigen presentation pathways of transporters associated with 
antigen processing (TAP). KLN 205 squamous carcinoma cells derived from DBA/2 
mice. The murine cell line EL4 (H-2b) is a lymphoma cell line (kind gift from Prof. 
Christopher Klein, MHH) and was grown in 10% DMEM. HEK293 cells are human 
embryonic kidney cells from the ATCC, (Rockville, MD, USA). 
 
5.3 Creation of stable cell line 
 
Plasmid MMP-OVA-IRES-GFP was a kind gift from Dr. Martin Sauer (MHH). Cells 
were seeded one day before transfection. Co-transfection of MMP-OVA-IRES-GFP 
(4 μg) and retrovirus pseudotyped with vesicular stomatitis virus (VSV G) (2 μg) and 
gag-pol (2 μg)) plasmids into producer cell line Phoenix-Amphoteric packaging cell 
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line ATCC (Rockville, MD) was carried out using the lipofectamine or calcium 
phosphate method by transient transfection. After 48 hrs, the cellular supernatant was 
collected over a period of a further 48 hrs.  For retroviral transduction of the CMT64 
cell line, supernatant containing viral particles was centrifuged at 2000 rpm for 10 
minutes and taken 1.5 ml of virus-containing supernatant and 1.5 ml DMEM, plus 
10% fetal calf serum (FCS), were added together in the presence of 8 μg/ml 
polybrene. The cells were incubated in an incubator at 37°C for 3 hrs. After 4 days, 
green fluorescent protein (GFP)-expressing cells were sorted and cultured. The new 
cell line CMT64-OVA-IRES-GFP is referred to as CMT64-OVA. 
 
5.4 Transfection procedure 
 
5.4.1 Lipofectamine-2000 
One day before transfection, approximately 2*106 cells in 5 ml of growth medium 
without antibiotics were seeded in 25 mm flasks so that they would be 90-95% 
confluent at the time of transfection. 
Dilute DNA (adenoviral transfection: 10 μg DNA; normal DNA transfections: 1 μg 
DNA) was added to 500 μl of opti-MEM reduced serum medium and mix gently. 
Lipofectamine-2000 was gently mixed before use, and then 18 μl of the 
lipofectamine-2000 was diluted in 482 μl of Opti-MEM. The solution was mixed 
gently once more and incubated for 5 minutes at room temperature (RT). The diluted 
DNA was then immediately combined with the diluted lipofectamine-2000, mixed 
gently and incubated for 20 minutes at RT to allow DNA-lipofectamine-2000 
complexes to from. 
The DNA-lipofectamine-2000 complexes (1 ml) were added to the flasks containing 
cells and medium. The flasks were gently agitated back and forth. 
The cells were incubated for 4-6 hrs at 37°C in an incubator and washed with 
phosphate-buffered saline (PBS), following which new medium with 10% FCS was 
added to the cells. After 24-48 hrs, the cells were ready to assay for transgene 
expression. In the case of adenoviral DNA transfection, the cells were incubated for 7-
10 days until a cytopathic effect was visible. 
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5.4.2 Calcium Phosphate Transfection 
 
2X HBS buffer (Transfection buffer) 
280 mM of NaCl (1,637 gm/100ml) 
50 mM BES (1,066 gm/100ml) 
1.5 mM Na2HPO4 (2H2O)   
PH - 6.95 to 7.2 to test for optimum transfection efficiency. This solution must be 
filtered to sterilize it and should be kept at 4oC. It should be brought to RT before use. 
 
CaCl2 preparation 
2.5 M CaCl2 (27.75 gm anhydrous CaCl2 or 36.75 gm CaCl2, (2H2O)) 
Both reagents were brought to RT before transfection. DNA was added to the CaCl2 
(300 μl) solution and kept for 10 minutes, following which an equal volume (300 μl) 
of 2X HBSS solution was added, and incubation was continued for 10 further 
minutes. This solution was added to the cells drop-wise. After overnight incubation, 
the cells were washed, and new medium was added. Transgene expression was 
measured 48 hrs later. 
 
5.5 Establishment of subcutaneous tumors 
A total of 5X106 KLN205 or CMT64 (OVA) cells were injected into the right flank of 
mice. After 7-10 days, tumors had grown to approximately 0.5-1cm. Mice were 
anesthetized with isofluorane, and viruses were injected intratumoral in a volume of 
100-150 μl. 
 
5.6 Lung metastasis  
100,000 CMT64 or CMT64-OVA cells were injected intravenously into C57Bl6 
mouse, two days before viroimmunotherapy. After 10-15 days, the lungs were full of 
metastases. In the treatment group, mice were sacrificed only when the experiment 
ended. 
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5.7 Bone-marrow-derived dendritic cell isolation and antigen 
pulsing 
Mice were sacrificed by cervical dislocation. Bone marrow was flushed out from the 
femur and tibia of mice as previously described (Weigel BJ et al, 2002). Briefly, red 
blood cells were lysed by ammonium chloride incubation, and single cell suspensions 
were then incubated at 2 x 106 cells/ml RPMI medium with penicillin and 
streptomycin, sodium pyruvate, non-essential amino acids, and 1 M 2-
mercaptoethanol at 37oC and 5% CO2 in 6-well plates with 150 U/ml 
granulocyte/macrophage colony-stimulating factor (GM-CSF; Sigma, Munich, 
Germany) and  
75 U/ml interleukin-4 (IL-4; Sigma, Munich, Germany) for 7 days or GM-CSF 
supernatant generated from EL4 stable cells. On day 8, dendritic cells (DC) were 
pulsed with tumor lysate or ovalbumin antigen (OVA). This was followed by 
maturation of DC by using anti-CD40 as a maturing agent on day 7. 
 
5.8 Spleen cell isolation  
Mice were sacrificed by cervical dislocation, and their spleens were taken. To make 
single cell suspension, spleens were crushed gently and transferred through 70-μM 
mesh into PBS. Splenocytes were centrifuged and resuspended in 1ml of PBS and 5 
ml of red blood cell (RBC) lysis buffer and centrifuged again. The pellet was 
resuspend in PBS and kept on ice until used. 
 
5.8.1 Erythrocyte lysis buffer 
4.14 gm of (NH4) Cl 
0.5 gm of KHCO3 
0.1 mM EDTA or 100 μl of 500 mM EDTA in 500 ml of distilled water. This solution 
must be sterilized for cell culture use. 
 
5.9 Flow cytometry 
1*106 cells were washed and incubated with Fc blcok (CD16/CD32) (2.4G2) (BD 
PharMingen, Heidelberg, Germany) at 4°C for 10 minutes to block nonspecific 
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binding of fluorochromes. The following directly conjugated antibodies were 
incubated with splenocytes at 4°C for 30 minutes with anti-CD11c, anti-CD8a, anti-
CD4, anti-CD25, anti-FoxP3, and labeled with Ova Pentamer-R-PE (only 10-minute 
incubation with pentamers, according to the protocol). 
OVA-reactive CTLs were tracked by using R-PE-labeled Pro5 MHC Pentamer H2-
Kb/SIINFEKL (ProImmune, Oxford, UK). After the cells had been stained, they were 
washed twice, centrifuged for 5 minutes at 1000 rpm, suspended in FACS buffer, and 
counted by FACS Caliber or FACSConto II. The data were analyzed by cell quest or 
FlowJo. 
 
5.9.1 FACS buffer 
0.1% bovine serum albumin (BSA), 0.1%NaN3, 10mM HEPES and 2mM EDTA in 
500 ml of PBS. 
 
5.9.2 MACS buffer 
One liter of MACS buffer was prepared with 0.5% BSA (5 gm), penicillin and 
streptomycin (10 ml), 1 mM EDTA, pH 8 (4 ml of 0.5 M stock), 4 ml of 1 M stock 
HEPES, 1 mM sodium pyruvate (10 ml of 100mM stock) and sterile-filtered for cell 
culture use. 
5.10  ELISpot 
ELISpot membrane was activated with 100 μl of 50% methanol/well for a few 
seconds and washed three times with PBS. Immediately, 100 μl/well of the capture 
antibody (0.25 μg of interferon-γ; IFN-γ) was added. The plate was covered with a lid 
and incubated overnight at 4oC. The primary antibody was washes out with PBS, and 
the membrane was blocked with RPMI plus 10% FCS for 1-2hrs. Spleenocytes were 
plated 2*105 cells/well and stimulated with different parameters and incubated in the 
ELISpot plate in a 37oC incubator without disturbance for 24-36 hrs. Plates were 
washed three times with PBS, followed by the addition of biotin-conjugated 
secondary antibody with 1% BSA in PBS and incubated at RT for 2 hrs. After a 
further three washes and incubation with streptavidin-HRP conjugate for 1hr, the 
plates were washed again extensively and then developed with DAB 1X substrate 
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with peroxidase 1X solution (both from Pierce, Germany) substrate until spots were 
developed. Development was stopped carefully with PBS. 
 
5.11 ELISA 
5.11.1 Measurement of total anti-adenovirus antibodies in serum 
ELISA plates (from Nunc Maxi Sorb) were coated with 108 particles/100μl/well and 
incubated overnight at 4oC. They were washed three times with PBS containing 0.1% 
Tween 20, blocked with 5% milk powder for 1 hr at RT, washed three times with 
PBS, and incubated with serum samples (serial dilutions in 100 μl/well) in duplicate 
for 2 hrs at RT.  The plates were washed three times with PBS, incubated with 
peroxidase-conjugated goat-anti-mouse IgG (H+L) (1:3000, 100 μl/well) for 2 hrs, 
washed three times, and finally incubated with TMB substrate (100 μl/well) until 
color developed. The reaction was stopped with 1M H3PO4 (50 μl / well). The optical 
density of the reaction products was measured at 450 nm. 
 
5.11.2 Cytokine ELISA 
The capture antibody was diluted to the working concentration in PBS without carrier 
protein. A 96-well microplate was immediately coated with 100 μl per well of the 
diluted capture antibody, sealed, and incubated overnight at RT. Each well was 
aspirated and washed with wash buffer, three times. The plates were blocked by 
adding 300 μl of reagent diluent to each well and incubated at RT for a minimum of 1 
hr, followed by three times with wash buffer. Sample or standards in reagent diluent 
(100 μl/well) were added to the plates, which were covered with an adhesive strip and 
incubated for 2 hrs at RT. The plates were washed three times with washing buffer. 
Detection antibody diluted in reagent diluent (100 μl) was added to each well, and the 
plate was covered with a new adhesive strip and incubated for 2 hrs at RT. 
Subsequently, the plate was washed three times with washing buffer. An aliquot of 
100 μl of the working dilution of streptavidin-HRP was added to each well, and the 
plate was once more covered and incubated for 20 minutes at RT in the dark, followed 
by three washes with wash buffer. Substrate (TMB substrate, BD OptE1A,) solution 
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(100 μl) was added to each well and incubated for 20 minutes at RT or until standards 
reached maximum color (in the dark). 
Following the addition of 50 μl of stop solution to each well, the plates were gently 
tapped to ensure thorough mixing and the OD of each well was immediately 
determined by using a microplate reader (Lambda Scan 200e; data analyzed by KC4 
software) set to 450 nm. 
 
5.12 Construction of adenoviral vectors  
 
The adenoviral plasmids were constructed by using shuttle-CMV vectors and pAd-
Easy-1 recombinant bacterial cells (BJ5183-AD-1 from Stratagene, Europe). The 
AdEasy-1 adenoviral plasmid contained all adenovirus-5 (Ad5) sequences, except for 
the E1 genes and E3 genes. pShuttle vector was used for the expression of murine 
MIP-1α and Flt3 ligand (these plasmids were a kind gift from Prof. Dan H Barouch, 
Harvard Medical School, Boston, USA). The pShuttle vector contains a multiple 
cloning site for the insertion of exogenous transgenes. This site is surrounded by 
adenoviral sequences (arms) that allow homologous recombination in Ad-Easy-1 
(Tong Chun He et al, 1998). The left arm contains Ad5 nucleotides 34,931-35,935 
(which mediate homologous recombination with pAdEasy vectors in E. coli), the 
inverted terminal repeat, and packing signal sequences (nucleotides 1-480 of Ad5) 
required for viral production in mammalian cells. The right arm contains Ad5 
nucleotides 3534-5790, which mediate homologous recombination with AdEasy 
vectors. An artificially created Pac I site surrounds both arms. 
BJ5183-AD-1 electroporation-competent cells are recombination-proficient bacterial 
cells carrying the pAdEasy-1 plasmid that encodes the Ad5 genome (E1/E3 deleted). 
These cells supply the components necessary to execute a recombination event 
between the pAdEasy-1 vector and pShuttle-CMV vector containing the murine MIP-
1α and Flt3 ligand, thus generating a recombinant adenovirus that contains these 
genes.  
pShuttle-CMV-MIP-1α and pShuttle-CMV-Flt3 ligand plasmids were taken (around 
2-5 μg DNA), linearized with restriction endonuclease Pme I, and then purified by 
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phenol-chloroform extraction and ethanol precipitation. The precipitated DNA was 
suspended in 5-10 μl distilled water depending on the precipitate, and 1 μl of DNA 
was transformed into electrocompetent BJ5183-AD-1 bacterial cells by using 
electroporation (Bio-Rad gene pulser electroporator). The cells were immediately 
placed in 900 μl of L-Broth (LB) and grown at 37oC for 60 minutes. Aliquots of 100 
μl of the cell suspension were inoculated onto agar plates containing kanamycin. After 
16-18 hrs of growth at 37oC, 25-50 small colonies were picked and grown in 3 ml of 
LB medium containing 50 μg of kanamycin and grown for 8 hrs at 37oC. The positive 
clones were screened and selected by restriction endonuclease digestions with BamH I 
and Hind III. Depending on the special restriction pattern of Hind III digestion, further 
positive clones (Figure 5.1) were selected and sequenced.  
 
 
Figure 5.1 Schematic Diagram representing the construction of MIP-1α 
and Flt3L expressing in adenoviral vector 
Ad-LacZ (contain β-Gal protein) was a kind gift from Dr. D. Brenner and Dr. K. 
Streetz. hTERT-Ad virus was constructed by Dr. Thomas Wirth from our lab (Wirth T 
et al, 2003). hTERT is the catalytic component of human telomerase reverse 
transcriptase and is not expressed in primary somatic cells, whereas the majority of 
cancer cells have reactive telomerase following the transcriptional up-regulation of 
hTERT. The hTERT-promoter drives the production of the E1A protein of the 
adenovirus.  
 
5.12.1 Large-scale production, purification, and titration of recombinant 
adenoviruses 
Approximately 1.5 million cells (HEK 293) were plated in 25cm2 flasks without 
penicillin and streptomycin and allowed to reach 90% confluency, 24 hrs before 
transfection with Lipofectamine 2000. Cells were washed with optiMEM medium and 
CMV- Pr mFlt3L Ad-backbone ITR ITR 
    mMIP1-al  pha  Ad5-backbone CMV- Pr   ITR   ITR 
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3 ml of optiMEM medium and kept in an incubator at 37°C. A sample of 10 μg of 
Pac1-digested (overnight digestion) adenoviral DNA containing the gene of interest 
and purified by the phenol-chloroform method was transfected and further followed 
according to the protocol provided with kit. After 7-10 days, when cytopathic effects 
were visible, cells were harvested, freeze/thawed three times and reinfected HEK 293 
cells.  
The plaque-purified adenoviral recombinant was used to infect HEK293 cells grown 
in 250 ml culture flasks when cells were 80% confluent. After 48 hours, when the 
cytopathic effect was visible, the cells were collected, and the pellet was resuspended 
in PBS. The cell-sludge was freeze-thawed three times. The debris was then separated 
by low-speed centrifugation, and the supernatant containing the virus was layered 
onto two discontinuous CsCl gradients and centrifuged at 27000 rpm for 4 hours in a 
Beckman LE80K ultracentrifuge. The virus band was then collected and stored in 
storage buffer. The OD of the harvested fractions (500 μl) was measured by 
spectrophotometry (at 260 nm) and titrated by Rapid Titer assay carried out by 
infecting 293 cells with a serial dilution of virus ranging from 10-2-10-7, followed by 
analysis with the kit provided. 
The virus stock was used immediately or stored at –20oC in storage buffer. 
 
5.12.2 Reagents 
CsCl gradient preparation 
1.2 gm/ml CsCl and 1.4 gm/ml CsCl were prepared as follows: 
1.2 gm/ml  13.25 gm CsCl 
1.4 gm/ml  26.75 gm CsCl 
were weighed separately and to each was added 0.5 ml of 1 M Tris, pH 7.5. Each 
solution was made up to 50 ml with distilled water and sterile-filtered.  
The gradient was prepared by layering 3.5 ml of 1.4 gm/ml CsCl on the bottom of 
tube and 3.5 ml of 1.2 gm/ml as the upper layer, followed by the virus-containing 
lysate, and centrifugation for 4 hrs in a Beckman ultracentrifuge. After 4 hrs, two 
distinct layers were observed; the bottom layer held the transgene-containing virus 
and was collected gently by making a small hole with a 26-gauge needle in the 
centrifuge tube, whereas the upper layer contained contaminating wild-type virus and 
  27  
 
 
 
Material and Methods 
 
was discarded. After collection of virus, 2X storage buffer was added, depending on 
the volume of the virus-containing layer, and kept at –20oC. 
 
2X storage buffer for 10 ml (virus) 
1 M Tris PH-8.0 100 μl 
5 M NaCl  200μl 
1 M MgCl2  10 μl 
Glycerol  5 ml 
H2O   4.59 ml 
10% BSA  100 μl  
(sterile-filtered) 
 
Dialysis buffer for 2 liters (virus) 
20 ml of 1M Tris, pH 8.0 
2 ml of 1 M MgCl2 
56 ml of 5 M NaCl or 16.36 g NaCl made up to 2 liters with distilled H20. 
 
5.12.3 Rapid Titer Assay (for titrating adenoviruses) 
 
One day before experiments, 1ml of healthy HEK293 cells (2*105) were seeded in 
each well of a 24-well plate in DMEM, 10%FCS. With medium as the diluent, 10-fold 
dilutions of the viral sample were prepared from 10-2 to 10-7 ml. Aliquots of 100 µl of 
the viral dilution were added drop-wise to each well in duplicate. The cells were 
incubated at 37oC in 5% CO2 for 48hrs. The medium was aspirated, and the cells were 
fixed gently by adding 1 ml ice-cold 100% methanol to each well at –20oC for 10 
minutes, followed by a rinse 1 ml of PBS +1%BSA. Anti-hexon antibody (1:2000 in 
PBS + 1 %BSA) was added to each well and incubated at 37oC in a shaker at 100 
rpm. The primary antibody was aspirated, and the wells were washed gently three 
times with PBS + 1% BSA. Rat anti-mouse antibody (HRP conjugate; 1:500 in 
PBS+1%BSA) was added to each well and incubated at 37oC in a shaker at 100 rpm. 
Prior to removal of the secondary antibody, the DAB working solution was prepared 
by diluting 10X DAB substrate (stored cold) 1:10 with 1X stable peroxidase buffer 
and allowing the DAB working solution to come to room temperature. The secondary 
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antibody was aspirated, and each well was gently rinsed three times, followed by 
incubation in 250 μl of DAB working solution at R
solution was removed and replaced by 1ml PBS for storage at 4oC. Ten fields of 
brown and black positive cells were counted by using microscope with a 20X 
objective and the mean number of positive cells in each well was calculated.  
The infectious units (ifu/ml) for each well were calculated as follows: 
 
(I
5.13 Replicat
 
5.13.1 Quantitation of
A total of 2*105 KLN and CMT64 cells were infected with various multiplicities of 
infections (MOIs) ranging from 0.1 to 10 MOI. After 48hrs, cells were harvested and 
freeze-thawed to release infectious particles. The supernatant of the freeze/thaw lysate 
was used to i
were visible. The 
 
5.13.2 In vitro Ad-Luciferase expression 
A total of 600,000 KLN and CMT64 cells were seeded in 60 mm plates and co-
infected with 1 MOI of hTERT-Ad or control virus in combination with 1 MOI of Ad-
Luciferase (replication defective). After 24, 48, and 72 hrs infection, cells were 
harvested and analyzed by luminometry (Lumat LB 5901, Berthold ) for luciferase 
expression (Luciferin from Applichem, Germany).  
 
5.13.3 Luciferin preparation for in vitro replication assay 
A stock solution was prepared by dis
T for 10 minutes. The DAB 
nfected cell/field) x (fields/well) 
Volume of virus (ml) x (dilution factor) 
 
ion of murine tumor cells 
 infectious particles in tumor cells  
nfect 293 cells, which were incubated for 48 hrs when cytopathic effects 
preparation was further stained by using the Rapid Titer kit for 
infectious particles. 
solving 10 mg of luciferin in 1.325 ml of distilled 
water. For the working solution, a 1:1000 (25 mM) dilution of the stock was used and 
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always kept at –20°C: This was brought to RT before using, since luciferase 
expression is temperature sensitive. 
 
5.13.4 In vivo imaging of Ad-Luciferase expression  
Mice were subcutaneously injected with 5*106 KLN205 or CMT64 tumor cells in the 
right flank. When tumors reached approximately 1 cm in diameter, mice were injected 
intratumoral (i.t.) with hTERT-Ad virus or control virus in combination with Ad-
Luciferase virus, each injection containing 1*109 and 1*109 infectious viral particles 
and in some cases 1*109 and 1*108 viral particles.  
After i.t. injections, mice were imaged for Luciferase expression every day until 8 
days. Then, 4.5 mg of D-Luciferin (Applichem, Germany) in 100 μl of RPMI medium 
was co-injected with ketamine and Rampum intraperitoneal. After 10 minutes, images 
were captured with the IVIS imaging system series 200 by using living imagev2.5 
software (Xenogen, USA), and photon emission values were calculated as 
recommended by the manufacturer. 
 
5.14 In vivo CTL killing assay 
 
Cytotoxic activity and specificity of CTL were determined by using a carboxy 
fluorescein succinimidyl ester (CFSE)-based in vivo killing assay as previously 
described (14). Untreated mice were used as controls. Target cells were prepared by 
using splenocytes from Black 6 mice. RBC-depleted splenocytes were pulsed with 
SIINFEKL peptide (1 μg/spleen) and incubated for 60 minutes at 37oC. Coated 
splenocytes were intensely labeled with high levels of CFSE (Molecular probes, 
Germany) at a final concentration 10 µl of 5 μM. As a control, non-coated splenocytes 
were weakly labeled at a lower concentration of CFSE 1 µl of 5 µM. The coated and 
non-coated fractions were mixed 1:1 and then injected intravenously at 2 x 107 
(together) cells per treated or untreated mouse. Specific in vivo cytotoxicity was 
determined by flow cytometric analysis of CFSE-positive cells within spleens that 
were harvested 18 hrs later. The ratio r between CFSEhi and CFSElo cells was 
calculated for determining the cytotoxicity of the effector cells.  
Cytotoxicity was calculated by the formula [1-(runprimed / rprimed)] x 100.  
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5.15 Immunohistochemistry 
 
Immunofluorescence analysis allows the investigation and characterization of tumor 
and lung tissues in terms of the proteins expressed on the surface of cells that have 
infiltrated into the tumor bed. The method is especially valuable in detecting 
infiltrating cells into the tumor and lungs. Immunofluorescence reveals even a small 
number of antigen-positive cells against a largely negative background. Two methods 
of fixation were used (1) methanol:acetone, and (2) paraformaldehyde (suitable for 
intracellular proteins). 
 
Paraformaldehyde fixation solution:  
A mixture of 0.4 g paraformaldehyde and 10 ml PBS was heated at 60°C and stirred 
until the solution became clear. It was then cooled to RT (prepared shortly before 
use). 
 
Preparation of sodium citrate buffer: 
(10 mM sodium citrate, 0.05% Tween 20, pH 6.0): 
Tri-sodium citrate (dihydrate)   2.94 g 
Distilled water      1,000 ml 
2.94 g of Tri-sodium citrate was completely dissolved in 1000 ml distilled water. The 
pH was adjusted to 6.0 with 1 N HCl, and then 0.5 ml Tween 20 was added and mixed 
well. Sodium citrate buffer was stored at RT for 3 months or at 4°C for longer storage. 
 
DAPI (4,6-diamidino-2-phenylindole) solution (Sigma):  
1:500 dilutions were prepared in PBS and stored in the dark at 4°C. 
 
Fluorescence microscope:  
The model Leica DM 3000 was used for capturing fluorescence and hematoxylin and 
eosin (H & E) stained images of tissue sections. 
 
Fixation and staining of tissue:  
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Cryosections (5 μm thick) of tumors were cut on a cryostat, attached to Super Frost 
Plus slides, and fixed in methanol:acetone for 10 min at –20oC or in 
paraformaldehyde for 20 minute at RT. The sections were washed with PBS, three 
times, permeabilized with Triton-X 100 (1%) for 5 min (10 ml PBS+100 μl Triton-X 
100), and then rinsed (2x3 min) with PBS. The cell membranes were polarized with 
0.1% glycine for 5 min (100 mg glycine in 100 ml PBS). The sections were then 
washed (2x3 min) with PBS. To prevent unspecific binding, the slides were incubated 
with FCS in a humidified chamber at RT for 60 min. Aliquots of 60-100 μl of the 
primary antibody were prepared by dilution in PBS (the optimal dilution of each 
antibody was determined separately). The sections were incubated with the primary 
antibody in a humidified chamber at 4°C overnight, followed by gentle washing (three 
times) with PBS. Aliquots of 100 µl of the secondary fluorescence-conjugated 
antibody were prepared by dilution in PBS (the optimal dilution for each was 
determined separately). The sections were incubated with 100 µl secondary antibody 
at 37°C in a humidified chamber for 60 min, rinsed three times with PBS at RT, 
incubated with 200 µl DAPI solution for counter-staining of the nuclei in a humidified 
chamber at 37°C for 10 min, rinsed three times with PBS at RT, mounted in mounting 
medium (MOVIOL), and analyzed by using a fluorescence or confocal microscope. 
 
Staining of paraffin sections:  
Paraffin-embedded tissue sections were deparaffinized in two changes of xylene (4 
min each), hydrated in two changes of 100% ethanol for 4 min each, followed by 
changes in 95% and 80% ethanol for 2 min each and a rinse in distilled water for 2 
min. In a water bath, a staining dish containing sodium citrate buffer was pre-heated 
until the temperature reached 98°C. Slides were immersed in the staining dish and 
incubated for 60 min. The staining dish was removed from the water bath, and the 
slides were allowed to cool for 20 min. The tissue sections were rinsed in washing 
buffer (2x2 min) and blocked with normal FCS for 60 min at RT. FCS was removed 
from sections carefully, taking care not to dry the section. Primary antibody was 
added at the appropriate dilution and incubated overnight at 4°C. Sections were  
rinsed in washing buffer (3x5 min). Secondary antibody was added and incubated for 
1 hr at RT and then rinsed with washing buffer (3x5 min). Sections were counter-
stained with DAPI for 10 min, rinsed again with washing buffer three times, and 
mounted with mounting medium.  
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Hematoxylin-Eosin (H & E) staining 
Cryosections of lung (7µm) were mounted on Super Frost Plus Gold slides or 
polylysine-coated slides (Menzler Glaeser, Braunschweig, Germany), air-dried for 20 
minutes, and immediately fixed in 10% neutral buffered formaldehyde (Carl Roth, 
Karlsruhe, Germany) for 20 minutes. After being washed with running tap water for 3 
minutes, the sections were stained with Mayer´s hemalaun (Merck, Darmstadt, 
Germany) for 10 minutes. After differentiation in freshly prepared 3.75% HCl (in 
70% ethanol), the sections were washed with running tap water for another 5 minutes, 
dehydrated in 70% and 90% ethanol for 2 minutes, respectively, stained with 
alcoholic eosin (containing 0.1% phloxine in 90% ethanol; Sigma-Aldrich, Steinheim, 
Germany) for 5 minutes, dehydrated in 100% ethanol and xylene, and finally mounted 
with Entellan New (Merck, Darmstadt, Germany) mounting medium.  
Images were acquired with a Leica DM 3000 Microscope for the “stitching” of 
images from lung sections; different parts of the organ were taken and manually 
stitched with Adobe Photoshop.  
 
5.16 Tumor infiltrating dendritic cell isolation (TID) 
 
DBA/2 mice were subcutaneously injected in their right flank with 5*106 KLN205 
tumor cells. Tumors were treated with various viruses when they reached 
approximately 0.5-1 cm. After 7 days, tumors were removed, and tissues were cut into 
small fragments and incubated in 1 mg/ml collagenase (PAN biotech, Germany) at 
37oC for 45-60 minutes. Single cell suspensions were prepared by depressing the 
digested tumor tissue, added to RPMI medium with 10% FCS, and incubated for 4 hrs 
in 37oC. Non-adherent TID cells were then purified anti-CD11c microbeads (Miltenyi 
Biotec, Germany) according to the manufactures instructions and adherent cells were 
removed (tumor cells). These purified TID cells were further stained with anti-CD11c, 
anti-CD40, anti-86, anti-CD83, and anti-MHC-II anti-sera. 
 
5.16.1 Tumor lysate pulsing 
Briefly, CMT64 tumor lysates were prepared as follows. CMT64 cells were 
resuspended in the same medium in which they were grown (approximately 1 ml), 
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freeze/thawed three times, and centrifuged for 5 minutes at 1000 rpm to remove 
cellular debris. The supernatant was taken as the tumor lysate for pulsing T cells and 
dendritic cells (DCs). For antigen-specific stimulation of DCs, either peptides or anti-
CD40 antibody (or some times both) were used. 
 
5.17 Reagents and antibodies used 
Alexa 488     FITC   Molecular Probes 
H-2Kb SIINFEKL pentamers   R-PE   Proimmune 
anti-Mouse CD3e    PE   145-2C11 
anti-Mouse CD4    FITC   L3T4 
anti-Mouse CD8a    FITC   53-6.7 
anti-Mouse CD11b    FITC   M1/70 
anti-Mouse CD11c (Integrin ax)  APC   N418 
anti-Mouse CD11c (Integrin ax)  Biotin   N418 
anti-Mouse monoclonal CD16/CD32 (FcγIII/II Receptor) (Fc BlockTM)BD 
anti-Mouse CD19    Biotin   MB19-1 
anti-Mouse CD25 (IL-2 Rezeptor α)  PE   PC61.5  
anti-Mouse CD40    FITC   HM40-3 
anti-Mouse CD40    unconjugated 1C10 
anti-Mouse CD80 (B7-1)   PE   16-10A1 
anti-Mouse CD83    PE   Michel-17 
anti-Mouse CD86 (B7-2)   FITC   GL1 
anti-Mouse/Rat Foxp3   APC   FJK-16s 
  
Goldener syrian Hamster Isotype control  PE   -/- 
Rat IgG2a Isotype control    FITC   eBioscience 
Rat IgG2a Isotype control    PE   eBioscience 
Rat IgG1 Isotype control   FITC   eBR2a 
Rat IgG Isotype control   APC   eBioscience 
anti-Mouse polyvalent IgG    Peroxidase  Zymed 
anti-Mouse Interferon-gamma  unconjugated  AN-18, 
eBioscience 
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anti-Mouse Interferon-gamma  Biotin   R4-6A2, 
eBioscience 
anti-Mouse MHC class II (I-A/I-E)  APC   M5/114.15.2, 
eBioscience 
anti-Mouse MHC class I, H-2Kd  FITC   SF1-1.1, BD 
PharMingen 
anti-Mouse MHC class I, H-2Kb  FITC   AF6-88.5, BD 
PharMingen 
anti-Mouse MHC class I, H-2Db  Biotin conjugated KH95, BD 
PharMingen 
Rat IgG2a κ isotype control      BD PharMingen 
Rat IgG2b κ isotype control      BD PharMingen 
Hamster IgG1, κ isotype control     BD PharMingen 
Anti-Mouse Rae pan specific   APC   R&D Systems 
Hamster anti-Mouse CD-3ε   unconjugated  BD PharMingen 
Flt3 Ligand ELISA Kit      R&D Systems 
MIP1α ELISA Kit       R&D Systems 
Biotinylated mouse anti-hamster cocktail    BD PharMingen 
Hamster anti-Mouse CD11c   Clone HL3 (IHC) BD PharMingen 
CellTrace CFSE cell proliferate kit     Molecular Probes 
CD11c (N418) MicroBeads      Miltenyi Biotec 
Streptavidin-FITC 
Streptavidin-PE 
Streptavidin-PE-Cy7 
Streptavidin-PerCP       BD PharMingen 
Streptavidin-APC 
Streptavidin-APC-Cy7 
TMB Substrate       BDOptE1A 
DAB Substrate       Pierce 
Peroxidase 1X        Pierce 
BD Cytofix/cytoperm       BD  
Collagenase        PAN Biotech 
OCT Compound       Sakura  
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D-Luciferin, Sodium salt      Applichem,Germany 
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6 Results 
 
6.1 Replication kinetics of conditionally replicating adenovirus in 
murine tumor cells measured by using coinfection of Ad-
luciferase-expression  
 
To assess replication kinetics in vitro, KLN205 and CMT64 cells were infected with 
conditionally replicating virus (hTERT-Ad) and control virus Ad-LacZ in 
combinations of replication-deficient luciferase-expressing Ad5 virus with each MOI 
of 1 and harvested at 24, 48 and 72 hrs. Harvested cell lysate was analyzed for 
luciferase expression and revealed that KLN205 cells had higher luciferase expression 
than CMT64, thereby revealing that hTERT was replicated to a greater extent in KLN 
than in CMT64. Luciferase expression was high at 48hrs and decreased at 72 hrs 
because of the cytopathic effect of the virus (Figure 6.1 and 6.2); the control virus 
exhibited no replication. 
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Figure 6.1 KLN205 squamous carcinoma cells were infected with the indicated 
viruses in combinations of control virus, hTERT-Ad and Ad-Luciferase. After 
24, 48, and 72 hrs cells were analyzed for luciferase expression 
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Figure 6.2 CMT64 small lung carcinoma cells were infected with the 
indicated viruses in combinations of control virus, hTERT-Ad and Ad-
Luciferase. After 24, 48, and 72 hrs cells were analyzed for luciferase 
expression 
 
To assess the replication of conditionally replicating virus in murine tumor cells, 
KLN205 and CMT64 cells were plated at 2*105 cells /well/ml in 24 well plate. Next 
day, the cells were infected with different MOIs from 0.1 to 10. After 48 hrs, cells 
from each well were harvested separately in the same medium, freeze/thawed three 
times to release viral particles into the medium, and centrifuged for 5 minutes at 1000 
rpm at 4oC. Aliquots of 100μl supernatant was taken to infect HEK 293 cells in order 
to assess infectious particles by using Rapid Titer assay kit according to the protocol 
described above. The results showed that KLN205 and CMT64 tumor cells were 
permissive to replication and lysis by producing viral particles upon infection with 
low MOIs. KLN205 produced more viral particles than CMT64, which further 
confirmed that murine tumor cells were able to replicate human viruses and to 
produce virions (Figure 6.3). These results correlated with in vitro luciferase 
expression in cells with combinations of hTERT-Ad and control virus. 
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Figure 6.3 Monolayers of KLN205 and CMT64 cells were infected with an MOI 
of 0.1-5.0. Virus production was assessed by TCID assay after 24 and 48hrs 
infection, showing hTERT-Ad virus replication in murine tumor cells. 
 
 
6.2 Bioluminescence imaging of co-infected subcutaneous tumors 
 
To analyze the in vivo replication efficiency of hTERT-Ad virus in murine tumor 
cells, KLN205 and CMT64 cells were injected subcutaneously (s.c.) in the right flank 
of DBA/2 and C57Bl6 mice respectively. These cells grow rapidly in mice and are 
difficult to treat, despite the use of a variety of treatments. Conditionally replicating 
oncolytic virus featuring the hTERT promoter, the catalytic subunit of telomerase, 
which is expressed in most tumor cells, and which drives the E1A protein of 
adenovirus (hTERT-Ad, 1*109 PFU), and a control LacZ-Ad or Ad-GFP (1*109 PFU) 
virus, which is deficient in replication, were coinjected with replication-deficient Ad-
luciferase (5*108 PFU) into subcutaneous tumors (intratumoral injections), when 
tumors had grown to about 1 cm in diameter. After 24hrs of virus injection, treated 
tumors showed photon emission, suggesting the efficient transduction and replication 
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of virus in tumor cells and the subsequent in vivo conversion of D-luciferin by 
luciferase.  
Imaging of tumors on subsequent days showed an increase in the conversion of D-
luciferin by luciferase, suggesting that viral particles increased with conditionally 
replicating hTERT-Ad virus compared with replication-deficient LacZ-Ad control 
virus in DBA/2 mice model (Figure 6.4a, 6.4c) and in CMT64 (Figure 6.4b). 
These results indicate that the presence of a replicating virus with an E1-deleted (Ad-
Luciferase) virus allows the replication of both viruses, whereas replication-deficient 
LacZ-Ad control virus values are low throughout the experiment because of 
replication deficiency. The increase in the replication-deficient control virus could be 
attributable to the transduction efficiency of the virus but not to the replication of the 
virus when compared with the in vitro replication assay and luciferase expression 
assay described above. 
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Figure 6.4 Mice were s.c injected with KLN205 and CMT64 cells. Tumors 
were treated with Ad-Luciferase and hTERT-Ad. (a) Photon emission in 
KLN205, (b) Photon emission in CMT64 and (c) In vivo bioluminescence 
of subcutaneous tumors 
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6.3 Construction and expression of Ad-MIP-1α and Ad-Flt3L 
proteins in vivo  
First we have constructed murine MIP-1α and Flt3L in adenoviral vectors. To 
determine the expression of adenoviruses expressing MIP-1α and Flt3 ligand, 
dialyzed viral particles were injected at 1*109 pfu intravenously (i.v.) into DBA/2 
mice. Serum samples were collected at days 5 and 10 and tested for secretion, stability 
and survival of viral particles. MIP-1α secretion was decreased by day 10, whereas 
Flt3L secretion was constant on day 10 (Figure 6.5a, 6.5b). 
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Figure 6.5a Mice were injected with 1x 109 pfu of Ad- MIP-1α. Serum samples 
were collected at days 5 and 10. ELISA was performed to test secretion of MIP-
1α. 
Figure 6.5b Mice were injected with 1x 109 pfu of Ad-Flt3L. Serum samples were 
collected at days 5 and 10. ELISA was performed to test secretion of Flt3L. 
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6.4 Infiltration of dendritic cells into tumor tissue allows efficient 
antigen presentation in oncolytic therapy 
 
Dendritic cells (DCs) are critical for priming adaptive immune responses to foreign 
antigens, but harnessing these cells in vivo to enhance immunogenicity against cancer 
cells has not been studied in oncolytic virotherapy. Here, we used replication-
defective adenovirus expressing macrophage inflammatory protein 1α (MIP-1α), a 
chemotactic factor that mobilizes DCs, and fms-like tyrosine kinase 3 ligand (Flt3L) 
to expand DCs in vivo to enhance the immunogenicity of antigens of tumors 
experiencing ongoing replication with conditionally replicating hTERT-Ad virus. 
MIP-1α is able to recruit immune cells, such as T cells and DCs, to the site of 
injection. Most of these cells are immature in status. Flt3L is a potent growth factor 
for DCs and is known to expand DCs in vivo in humans and mice and to expand 
mature DCs. 
In this study, we hypothesized that conditionally replicating virus in tumor tissue lyse 
the tumor tissue. Expression of MHC-I antigens on the surface of virus-infected cells 
down-regulated by adenovirus might cause further inhibition of antigen presentation 
and immune response against tumor antigens. Hence, our interest was to recruit 
immature DCs in ongoing virotherapy with adenovirus expressing MIP-1α and to 
expand them by using Flt3L to enhance antigen-specific immune responses in 
virotherapy.  
We determined whether a combination of these chemotactic and growth factors 
expressed in adenovirus would lead to the recruitment and expansion of infected 
tumor bed with DCs. 
We used KLN205 (DBA/2 mice) and CMT64 (C57Bl6 mice) cells with 25% infected 
and 75% uninfected cells injected s.c. After 6 days, tumors were harvested in OCT 
compound and kept at –80oC. Tumors were cut by cryostat into 5 μm serial sections 
and fixed on Super Frost slides. Immunohistochemistry of tumor sections revealed the 
presence of a few local cellular infiltrates with hTERT-Ad, Ad-MIP-1α, and Ad-Flt3L 
alone. Co-injection of Ad-MIP-1α and Ad-Flt3L resulted in large clusters of tumor-
infiltrating immune cells. Further, we stained these tissues with the CD3e and CD11c 
antibodies and found that the recruited cells were T lymphocytes and DCs. The 
combination of chemotactic factor MIP-1α and DC growth factor Flt3L resulted in 
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greater number of T lymphocytes and DCs compared with virotherapy alone or 
treatment with a single chemokine. (Figure 6.6) 
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MIP-1α-Ad & 
Flt3L-Ad 
Figure 6.6 Infiltration of immune cells by MIP-1α-Ad & Flt3L-Ad. 
 
KLN205 cells were infected with an MOI of 25 and injected s.c. into DBA/2 mice. 
Tumors were harvested at day 6 and stained for dendritic cell (anti-CD11c) and 
T cell (CD3) markers. Magnification 20X. 
 
6.5 Migration and expansion of DCs enhance immune response to 
tumor antigens in virotherapy 
 
Oncolytic therapy with conditionally replicating virus causes cell death in tumors 
depending on the replication efficiency of the tumor cells. hTERT-Ad virus has been 
shown to replicate efficiently in human tumor cells. 
In our experimental model, we used murine tumor cells KLN205 and CMT64-OVA. 
Tumor cells were injected s.c. into either DBA/2 or C57Bl6 mice. When tumors had 
grown to around 0.5-1 cm in size, tumors were treated intratumoral with hTERT-Ad, 
Ad-MIP1α, Ad-Flt3L, or control virus Ad-LacZ alone or with various combinations 
of hTERT/Ad-MIP1α, hTERT/Ad-Flt3L, hTERT/Ad-MIP1α/Flt3L, and control virus 
Ad-LacZ. All virus combinations were always normalized to 2*109 with control virus. 
We used hTERT-Ad at 1*109 and Ad-Flt3L and Ad-MIP1α each at 5*108 viral 
particles in 150 μl. We always supplemented with control virus to make up to 2*109 
viral particles in cases of single viruses used in our experimental setup. To evaluate 
immune response to tumor antigen, mice were sacrificed on day 14, and splenocytes 
were stimulated with either tumor lysate or ovalbumin peptide at 1 μg/ml. The cells 
were incubated for 48hrs. 
The results of the experimental approach with different combinations of chemokine 
and growth factors showed that single chemokine Ad-MIP1α or Ad-Flt3L or hTERT-
Ad virus exhibited an immune response to tumor antigen, but that a combination of 
Ad-MIP1α and Ad-Flt3L had synergistic effects by secreting high IFN-γ (Figure 6.7). 
 
 
 
Results 
 
These results indicate that the combination of virotherapy with immunotherapy not 
only enhances virotherapy efficacy, but also generates tumor antigen-specific immune 
responses in ongoing virotherapy. 
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Figure 6.7 Immune response against tumor lysate augmented by MIP-1α and 
Flt3L in oncolytic therapy. Intra-tumoral injection with hTERT-Ad, Ad-MIP-1α, 
or Ad-Flt3L or a combination of both cytokine viruses with oncolytic virus.  The 
immune response was measured by IFN-γ ELISpot assay. 
 
6.6 Migration and expansion of DCs enhances immune response 
against virus 
 
In this experimental approach, hTERT-Ad virus replication in KLN205 and CMT64 
cells was efficient and produced viral particles as shown in Fig 1 above. DC migration 
into tumor tissue after treatment with different combinations of MIP1α and Flt3L with 
hTERT not only showed captured tumor-associated antigen and produced antigen-
specific immune responses, but also revealed captured viral particles and produced a 
virus-specific CD8 T cell immune response, as shown by IFN-γ (Figure 6.8) secretion 
by mouse splenocytes upon stimulation with virus with an MOI of 100. 
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From these results, DC migration can be seen not only to enhance tumor antigen-
specific immune responses, but also viral antigen-specific immune responses as 
shown by IFN-γ secretion (ELISpot). Further modulation of the immune response to 
tumor antigen is however necessary. 
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Figure 6.8 Immune response against virus. Tumors were injected with various 
virus combinations and IFN-γ secretion was analyzed by ELISpot against virus. 
 
6.7 Modulation of immune responses by DC vaccination enhances 
tumor antigen-specific immune responses and reduces humoral 
immune response to virus 
 
DC vaccination is one of the most promising approaches for cancer therapy. To 
investigate whether DC vaccination could modulate the immune response toward 
tumor antigens in viroimmunotherapy, we investigated various sequence-specific 
treatments of viroimmunotherapy and subsequent DC vaccination, or vise versa. 
Mice were injected with s.c. CMT64-OVA tumors. When tumors had grown to 
approximately 0.5-1 cm, tumors were treated with viroimmunotherapy (injection of 
MIP1α/Flt3L/hTERT-Ad; 2X) for three days continuously, during a one-week time 
interval and, in another set up, one viroimmunotherapy and a subsequent vaccination 
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of DC loaded with peptide at 5*105 cells per mouse. Control groups were subjected 
only to DC vaccination and only to virotherapy (hTERT-Ad virus). 
The results for IFN-γ secretion show that viroimmunotherapy (1X) and a subsequent 
DC vaccination not only enhances tumor antigen-specific CD8 T cell responses, but 
also reduces humoral response to virus, which is highly important in a clinical setting 
to improve viral persistence in ongoing therapy. Treatment with viroimmunotherapy 
only showed no significant IFN-γ secretion compared with viroimmunotherapy plus 
subsequent DC vaccination. DC vaccination alone also resulted in no significant IFN-
γ secretion. These results suggest that viroimmunotherapy provides an inflammatory 
environment, which provides precondition for effective DC vaccination. (Figure 6.9) 
The major hurdle of virotherapy is the inactivation of viral vectors or the virus itself. 
Our aim has been to enhance the antigen-specific immune response to tumor antigens 
and to reduce the immune response to viral antigens in oncolytic virotherapy. 
Our experimental set up tested whether viroimmunotherapy and subsequent 
ovalbumin tumor antigen loaded DC vaccination could enhance the antigen-specific 
immune response and reduce antibody titers to adenovirus. Our results with 
viroimmunotherapy alone showed no significant antigen-specific immune response 
but high humoral immune response to adenovirus, which was measured by total IgG. 
The humoral immune response might inactivate viral persistence in mice, further 
reducing tumor antigen-specific immune responses. 
Interestingly, viroimmunotherapy and subsequent ovalbumin tumor antigen loaded 
DC vaccination enhanced IFN-γ secretion to ovalbumin-specific peptide and reduced 
viral antibody titers. However, ovalbumin peptide-pulsed DC vaccination and 
subsequently viroimmunotherapy (DC-viroimmunotherapy) also gave no significant 
immune responses to ovalbumin peptide and no significant reduction in viral antibody 
titers. 
In conclusion, viroimmunotherapy alone was not very effective, but 
viroimmunotherapy plus subsequent tumor antigen loaded DC vaccination was 
effective in eradicating established tumors and reducing anti-adenoviral antibody 
titers (Figure 6.10). 
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Figure 6.9 Viroimmunotherapy and subsequent DCs vaccination enhances 
tumor antigen-specific immune response. Combination of cytokines with 
virotherapy and subsequent antigen-specific pulsed DC vaccination (MFT-DC) 
enhances antigen-specific immune responses compared with viroimmunotherapy 
(MFT-MFT), virotherapy (hTert-DC), peptide-pulsed DC vaccination plus 
subsequent viroimmunotherapy (DC-MFT), and DC vaccination alone (DC-DC). 
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Figure 6.10 Anti-adenoviral antibody ELISA. Mice were injected with various 
combination of viruses as mentioned and DC vaccination (before or after 
viroimmunotherapy). After two weeks, serum was collected, and total IgG was 
measured by ELISA. 
 
6.8 Viroimmunotherapy expands cytotoxic T cells in vivo and kills 
antigen-specific target cells 
 
A cytotoxicity assay was performed to determine the presence of cytotoxic T cells 
(CTLs) in vivo. CMT64-OVA cells were injected s.c. and, when tumors were 
palpable, the tumors were injected with control virus, hTERT-Ad, and 
viroimmunotherapy. After two weeks, mice were injected with ovalbumin-pulsed 
splenocytes together with high CFSE, whereas control peptide (β-gal peptide) 
containing splenocytes were injected i.v. with low CSFE, with each population at 
1*107 (total of 2*107 cells). After 18 hrs, mice were sacrificed, and isolated 
splenocytes were examined, by fluorescence-activated cell sorting (FACS), for CFSE-
labeled cells and CD8 T cell populations for specific killing by CTLs. 
Mice from untreated control and hTERT-Ad-treated mice shown no killing of 
ovalbumin-pulsed target cells compared with viroimmunotherapy-treated mice. These 
results showed that MIP-1α-Ad and Flt3L-Ad viruses infiltrated and caused the 
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expansion of DCs into the tumor bed and then mature DCs migrated to lymph nodes 
where they activated naïve T cells to become CTLs, but the hTERT-Ad did not 
generate CTLs or only in extremely low numbers (Figure 6.11a, 6.11b). Thus, 
virotherapy alone is not effective for generating high enough numbers of CTLs, 
whereas a combination of immunotherapy is successful in generating effective 
antigen-specific lysis of target cells (Figure 6.11c, 6.11d).  
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Figure 6.11b In vivo cytotoxicity of target cells in virotherapy in cross-
presentation of tumor antigen. 
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Figure 6.11a In vivo cytotoxicity of target cells in virotherapy in cross-
presentation of tumor antigen. Mice were bearing s.c tumors with oval
expressing CMT64 cells. Splenocytes were labeled with CFSE hi (target cells
CFSE low (control) and injected i.v. into treated mice. After 18 hrs, splen
were analyzed for CFSE.  hTERT-Ad alone treated mice shown killing of t
cells by cross-presenting the ova peptide (SIINFEKL) expressing tumor antigen. 
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Figure 6.11c In vivo killing of target cells in viroimmunotherapy and DC 
vaccination. Mice were treated with different vaccinations and treated mice were 
injected i.v. with CFSE hi labeled target cells (ova peptide SIINFEKL) and CFSE 
low (control peptide). After 18 hrs, splenocytes were analyzed for CFSE. 
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Figure 6.11d In vivo cytotoxicity of target cells in viroimmunotherapy 
subsequent DC vaccination in cross-presentation of tumor antigen. 
 
6.9 In vivo maturation of DCs leads to migration of DCs to lymph 
nodes to activate naïve T cells 
To test that tumor-infiltrating immature DCs were matured by viral infection or the 
take-up of apoptotic tumor cells and migrated to lymph nodes to activate naïve T cells 
in order to generate an immune response, TIDs (tumor infiltrating dendritic cells) 
were isolated and purified by CD11c beads and analyzed by FACS for CD40 markers. 
The presence of MHC II, CD80, and CD83 was demonstrated by 
immunohistochemistry. 
An increase in the expression of maturation markers CD40, CD80, CD83 and MHC-II 
(Figure 6.12a, 12b, 12c) upon infection with MIP1α and Flt3L adenoviruses shown 
that TIDs had matured and migrated to lymph nodes to activate naïve T cells  
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Figure 4.12a 
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Figure 6.12a Expression of CD40 on TIDs after treatment with 
viroimmunotherapy 
 
Figure 6.12b Representative expression of CD40 on DCs after treatment 
with viroimmunotherapy 
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Figure 6.12c KLN205 s.c tumor sections were stained for maturation 
markers on TIDs 
 
6.10 Viroimmunotherapy and subsequent tumor antigen loaded DC 
vaccination inhibit established lung metastasis 
 
To investigate whether viroimmunotherapy and DC vaccination has any clinical 
relevance, we injected i.v. CMT64-ova tumor cells, two days before treatment. Mice 
were grouped into six groups as follows 
1. Untreated control, n = 6 
2. Only virotherapy (hTERT-Ad only), n = 6 
3. Viroimmunotherapy, n= 6 
4. Viroimmunotherapy and subsequent DC vaccination, n = 6 
5. DC vaccination and subsequent viroimmunotherapy, n = 6 
6. Only DC vaccination, n = 6 
Mice were treated intratumoral with viroimmunotherapy and vaccination with DCs 
pulsed with ovalbumin peptide (1 μg/ml) and stimulated with anti-CD40 overnight. 
CD11c-purified DCs were injected s.c. After 2 weeks, lungs were harvested, and 
sections prepared for H&E staining. 
Control Ad-LacZ Ad-MIP-1α Ad-Flt3L 
Ad-MIP-1α/ 
Ad-Flt3L 
MHC II 
CD80 
CD 83 
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Interestingly, untreated controls and mice subjected only to virotherapy exhibited no 
inhibition in lung metastasis, whereas viroimmunotherapy and viroimmunotherapy-
DC vaccination inhibited lung metastasis. The group treated with only 
viroimmunotherapy and subsequent DC vaccination showed an inhibition of more 
than 50% in lung metastasis (Figure 6.13a, 6.13b) and rule out that adenoviral protein 
infiltrated to lungs which further inhibited metastasis (Figure 6.14). 
 
Figure 6.13a Inhibition of established lung metastasis. Mice were injected i.v CMT64 
cells and treated viroimmunotherapy and DC vaccination. After last injection, mice 
were killed on day 14th and lung sections were stained with H & E. 
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Figure 6.13b Representative value of tumor nodules in lung after vaccination 
 
                 
   Lung        Tumor 
Figure 6.14 Adenoviral hexon protein staining of lung and tumor  
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6.11 Combination of oncolytic virotherapy and immunotherapy 
increases spleen size and eradicates established subcutaneous 
tumors  
Oncolytic therapy has shown that replicates in KLN 205 cells produce viral particles 
by various methods. We have studied whether this has any effect on tumor regression 
in the treatment groups. Control groups, PBS, and LacZ-Ad injected tumors grew 
continuously. Virotherapy and immunotherapy alone retarded growth. However, a 
combination of viroimmunotherapy resulted in almost total tumor regression (Figure 
6.15) and spleen size increased to twice that of the untreated group (Figure 6.16). 
 
 
Figure 6.15 Eradication of tumors after viroimmunotherapy. After treatment 
with the above combinations, mice were photographed at day 21. 
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Figure 6.16 Spleens were weighed at day 21 after treatment with the different 
combinations of viruses. 
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7 Discussion 
Several strategies have been used to eradicate solid tumors. Conventionally, cancer is 
treated with chemotherapy, radiotherapy, and the surgical removal of solid tumors. 
The genetic mutations responsible for carcinogenesis may increase the resistance of 
malignant cells to conventional treatments, thereby allowing the further survival of 
cancer cells and tumor growth (Fojo T, 2003). Increased knowledge of the molecular 
basis of cancer has also provided the possibility to exploit gene therapy as a novel 
strategy to treat cancer. The principle of gene therapy is to introduce, into a target cell, 
a therapeutic gene whose expression either stops or hinders the progression of the 
disease. 
 
The major obstacle to adenoviral therapy is the transduction of viral vectors into the 
total tumor mass. Tumor specific, conditionally replicating viruses are promising tools 
to overcome low tumor cell transduction (Kirn D et al, 2001, Wirth T et al, 2003). 
 
7.1  Efficient replication of conditionally replicating human 
adenovirus (hTERT-Ad) in murine tumor cells in vitro and in 
vivo 
 
Oncolytic viruses kill tumor cells by tumor-specific replication. Clinical data have 
shown the safety of the approach but also the need for improvements in potency. 
Here, we have investigated the effects of a conditionally replicating adenovirus that is 
under the control of the hTERT promoter, which drives the E1A protein of adenovirus 
and causes the replication of adenovirus specific to the tumor cells. Most of previous 
studies have examined conditionally replicating adenoviruses in xenograft models and 
the regression of tumor growth, but not the immune response to tumor antigen in 
immunocompetent mice.  
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In this study, we have shown the kinetics of conditionally replicating adenovirus 
(hTERT-Ad) in immunocompetent murine models. We have chosen two cell lines: 
KLN205, a squamous carcinoma cell line, and CMT64, a lung cell carcinoma, both of 
them cause’s lung metastasis. 
 
To assess the replication kinetics in vitro, KLN205 and CMT64 cells were plated with 
hTERT-Ad and replication-defective LacZ-Ad virus or in combination with 
replication-defective Luc-Ad viruses. Each virus dose was MOI of 1 (together always 
MOI 2). In this study, we hypothesized that, when replication-defective Luc-Ad 
occurred in combination with hTERT-Ad, both viruses would replicate when present 
in the same cell. Cells were infected with various viral combinations and analyzed at 
24, 48, and 72 hrs for luciferase expression. 
 
Replication-defective control LacZ adenovirus in combination with Luc-Ad virus 
showed no replication in KLN205 and CMT64 cells for all analyzed parameters in 
terms of luciferase expression. Interestingly, the combination of hTERT-Ad with Luc-
Ad showed a gradual increase in luciferase expression from 24hrs to 48hrs, but this 
then decreased by 72hrs (Figure 6.1, 6.2). The decrease of luciferase expression at 
72hrs was attributable to all cells having undergone lysis and the further non-
availability of new tumor cells to produce new viral particles (VPs). 
 
Furthermore, in order to reconfirm that whether these tumor cells replicated hTERT-
Ad virus and produce new virions, we performed a Rapid Titer Assay. KLN205 and 
CMT64 cells were infected with low MOI. After 48hrs, the cells were harvested and 
freeze/thawed three times to release viral particle into medium. The supernatant was 
used to infect HEK293 cells. After 48hrs, infected cell were stained with a Rapid Titer 
kit. These data showed that replication-defective adenovirus LacZ-Ad produced no 
new virions (Figure 6.3), whereas hTERT-Ad produced a high number of VPs at 
48hrs. 
 
An additional interest of mine has been to study the in vivo replication of the hTERT-
Ad virus in tumors. To this end, we injected KLN205 cells and CMT64 cells s.c. into 
DBA/2 and C57Bl6 mice respectively. When the tumors were palpable, 1*109 VPs of 
hTERT-Ad in combination of 5*108 Luc-Ad VPs were injected i.t., or control 
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replication-defective virus and Luc-Ad were injected i.t. with same number of VPs as 
for hTERT and Luc-Ad, respectively. After 24hrs, we measured luciferase expression 
by using the XENOGEN, IVIS System. The tumors showed photon emission at this 
time point, suggesting the successful transduction of tumor cells and the subsequent 
conversion of D-Luciferin by luciferase. Interestingly, in replication-defective viruses, 
photon emission was always constant as a small increase, whereas replication 
competent hTERT-Ad showed gradual increases in photon emission every day until 
day 5 and decreased slowly thereafter (Figure 6.4a, 6.4b and 6.4c). 
 
These data thus reveal that human telomerase-dependent conditionally replicating 
adenovirus replicates efficiently in murine tumor cells in vitro and in vivo and 
produces new VPs. 
 
7.2 Expression of Ad-MIP-1α and Ad-Flt3L 
To investigate the stability and expression of viruses expressing Ad-MIP-1α and Ad-
Flt3L, viruses were injected at 1*109 VPs i.v. into DBA/2 mice. Serum samples were 
collected at days 5 and 10. ELISA was performed for each cytokine. Ad-MIP-1α 
exhibited high expression at day 5, but this decreased by day 10, in comparison with 
irrelevant virus (Ad-LacZ).  The increase at day 5 was high because of the high 
transduction of virus in the liver. The decrease by day 10 showed the high 
immunogenicity caused by Ad-MIP-1α and the antiviral immunity stimulated by 
humoral response (Figure 6.5a). On the other hand, Ad-Flt3L expression increased by 
day 5 and was consistent until day 10 (Figure 6.5b), showing tolerance to adenovirus 
and that this tolerance persisted for long periods, thereby helping further longer 
periods of transgene expression. 
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7.3 Recruitment and expansion of DCs by expressing Ad-MIP-1α 
and Ad-Flt3 ligand in the tumor 
 
DCs are professional antigen-presenting cell that play a central role in priming the 
immune response to foreign antigens. However, the limited availability of DCs in 
various vaccine strategies impairs these therapeutic approaches. We have 
hypothesized that a combination of virotherapy with immunotherapy not only will 
improve virotherapy efficacy, but also will generate an anti-tumor immune response 
and cross-presentation of the tumor antigen. To assess this, we used replication-
defective Ad-MIP-1α to mobilize DCs into the tumor bed and replication defective 
Ad-Flt3L to expand the mobilized DCs (Sumida et al, 2004). Other studies have 
shown that tumor vaccines generated by the transfection of immune-regulating 
molecules in vitro and in vivo are also effective as a therapeutic vaccine in generating 
the host immune response against tumors in various models (Shilin Yang et al, 2004). 
Another investigation examining Ad-Flt3L expression alone has demonstrated that, in 
hepatocellular carcinoma cells, gene therapy by local injection of Ad-Flt3L is an 
alternative to genetically modified tumor cells for stimulating host immune responses 
(Wang H et al, 2005). 
 
As shown above, replication-defective virus in combination with hTERT-Ad virus can 
replicate and produce more virions (Figure 6.1 and 6.2). In our experimental set up, 
we injected tumor cells KLN205 and CMT64 s.c. into DBA/2 and CMT64 mice 
respectively. When tumors had grown to 1 cm in diameter, tumors were injected i.t. 
with 1*109 hTERT-Ad or 5*108Ad-MIP-1α or 5*108 Ad-Flt3L or a combination of 
Ad-MIP-1α /Ad-Flt3L. In some cases 25% infected and 75% uninfected with these 
combinations and injected s.c in DBA/2 and C57bl6 mice. Ad-LacZ was used as a 
control virus in order to keep the total dose of virus constant in all animals. On day 6 
after the viruses had been injected into tumors, the tumors were harvested to 
determine the migration of immune cells into tumor bed. Tumor sections were 
analyzed by immunohistochemistry with specific antibodies for DC cells and T cells. 
 
As shown in Figure 6.6, control Ad-LacZ-virus-infected cells showed no infiltration 
or a low number of immune cells. Ad-hTERT-infected cells showed a small 
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infiltration of DCs and T cells, whereas after treatment with Ad-MIP-1α or Ad-Flt3L 
alone, large number of DCs and T cells were observed. The combination of Ad-MIP-
1α and Ad-Flt3L resulted in even larger number of DCs and T cells infiltrating the 
tumors. Indeed, the coadministration of both cytokine viruses resulted in a greater 
than 10-fold increase in inflammatory cell number as compared with hTERT-Ad 
alone. Furthermore, the apoptotic cells produced by hTERT-Ad were accessible to 
these recruited DCs and T cells. 
 
These results demonstrate that Ad-MIP-1α or Ad-Flt3L alone recruit small number of 
DCs and T cells to the injected site. When these viruses are administered together, a 
massive number of DCs and T cells infiltrate the tumor. Probably Ad-MIP-1α recruit 
DCs and T cells, and Ad-Flt3L expanded these cells resulting in large number of DCs 
and T cells at the site of injection. 
 
7.4 Infiltration of DCs and T cells augments immune response to 
tumor antigens and viral antigens in virotherapy 
 
Our aim was to infiltrate and expand immature dendritic cells into the tumor bed 
where replication-competent virus could produce apoptotic tumor cells. Infiltrated 
immature DCs directly take up tumor antigens and mature by inflammation caused by 
viruses. These mature DCs migrate to draining lymph nodes (DLN) where they 
activate naïve T cells to generate antigen-specific immune responses. 
Here, we have used the antigen presentation pathway-deficient cell line CMT64 
together with transporter associated with antigen processing 1 gene deficient (TAP1). 
Expression of TAP1 in lung carcinoma cells increases tumor-specific immune 
responses and survival (Lou Y, 2005, Jefferies WA, 1993); others have shown TAP-
dependent MHC I presentation of exogenous antigen by bone marrow DCs (BMDCs) 
(Norbury CC et al, 1997). 
 
On the basis of this, we have hypothesized that the infiltration of DCs into tumor 
cells, in which ongoing replication of adenovirus (virotherapy) is taking place, would 
enhance tumor-specific immune responses by cross-presenting the tumor antigens 
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released by virotherapy. CMT64 tumor cell were injected s.c. into C57Bl 6 mice, 
which are defective in TAP expression. When tumors had grown to approximately 1 
cm in diameter, various combinations of viruses (control, Ad-hTERT, Ad-MIP-1α, 
and Ad-Flt3L and a combination of Ad-hTERT and cytokines) were injected i.t. 
(Figure 6.7). After 2 weeks, mice were killed, and their splenocytes were isolated. 
Viroimmunotherapy-elicited CD+8 T lymphocyte responses specific for the tumor 
lysate were assessed. As demonstrated in Figure 6.7, a single injection of virotherapy 
alone showed secretion of IFN-γ. Control mice treated with PBS exhibited no specific 
immune response, but virotherapy alone resulted in a high secretion of IFN-γ 
compared with cytokines alone. This could be that hTERT-Ad virus contains E1A 
gene under the control of hTERT promoter, which drives E1A expression specifically 
in tumor cells (Wirth T et al, 2003) and produces more E1A protein molecules and 
transduction of virus, further enhancing the immune response through various 
pathways. Recent studies have shown that adenovirus serotype 5 E1A expression 
sensitizes tumor cells to NKG2D-mediated NK cell lysis and tumor rejection in a 
murine model (Routes JM, 2005).  
Interestingly, the combination of a single cytokine with hTERT-Ad virus showed a 
synergistic effect, with high levels of IFN-γ being secreted. Infiltration of DCs and T 
cells into tumor bed and secretion of inflammatory cytokines by infiltrated cells 
would enhance the MHC expression on CMT64 cells, which mediates antigen specific 
immune response and target cell killing. Further, a combination of both cytokine 
viruses with hTERT-Ad showed an extremely high secretion of IFN-γ specific to 
tumor-associated antigens. The secretion of IFN-γ presented in Figure 4.7 is the mean 
value of 8 wells of each parameter.  
 
One drawback of virotherapy is the anti-viral immune response to viral vectors or to 
the virus. Since the migration and expansion of DCs enhances the anti-tumor immune 
response, we expected an anti-viral immune response too. As shown in Figure 6.8, 
treatment with a single cytokine, Ad-Flt3L, leads to a lower immune response to virus 
than treatment with Ad-MIP-1α alone. Moreover, in Figure 6.5a, MIP-1α can be seen 
to have more immunogenicity than Flt3L, i.e., Flt3L is more tolerance to virus. 
Nevertheless, the combination of both cytokines with hTERT-Ad results in a high 
anti-viral T cell responses (Figure 6.8). This reveals another of the major obstacle 
  66 
 
 
 
 
Discussion 
 
concerning the use of viral vaccine in tumor therapy, namely, that the strong viral 
antigens will dominate, thereby inhibiting responses to the subdominant tumor 
antigens. However, quenching of the immunodominant antigens is rarely seen with 
recombinant viral vaccines. Hence, a balancing/modifying the immune responses to 
tumor and virus are important in virotherapy (Carroll MW et al, 1997 and Paoletti E et 
al 1995).  
 
7.5 Modulation of immune responses by DC vaccination in a 
sequence specific manner enhances tumor-specific T cell 
responses and decreases the humoral response to viruses 
One chief barrier to cancer virotherapy is the anti-viral immune response, as discussed 
above. To break or modulate anti-tumor and anti-viral responses, we performed an 
elegant experiment, in which we injected s.c. the ovalbumin (SIINFEKL-H2Kb 
restricted) model antigen-expressing stable cell line CMT64-OVA and treated the s.c. 
tumors as follows. 
1. Control  
2. Viroimmunotherapy (hTERT/MIP-1α/Flt3L); in subsequent weeks, (MFT-
MFT) 
3. Viroimmunotherapy; in subsequent week, tumor antigen pulsed DC 
vaccination (MFT-DC) 
4. Tumor antigen pulsed DC vaccination; in subsequent week, 
viroimmunotherapy (DC-MFT) 
5. Virotherapy alone (hTERT-Ad-DC)  
6. Only tumor antigen pulsed DC vaccination  
M- MIP1α-Ad 
F-Flt3 Ligand-Ad 
T- hTERT-Ad 
 
Following treatment, splenocytes were isolated on 28th day and assessed for the 
cellular immune responses by IFN-γ ELISPOT. As shown in Figure 6.9, control and 
DC vaccination alone resulted in no detectable immune response, whereas 
viroimmunotherapy, viroimmunotherapy with subsequent DC vaccination, and DC 
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vaccination with subsequent viroimmunotherapy showed detectable ovalbumin 
antigen-specific immune responses. Interestingly, only viroimmunotherapy with 
subsequent ovalbumin antigen pulsed DC vaccination showed a three to four-fold 
increase compared with viroimmunotherapy and with DC-vaccination plus subsequent 
viroimmunotherapy. Viroimmunotherapy thus seems to provide a conditioned 
environment in the tumor and subsequent antigen pulsed DC vaccination leads to 
direct migration of DCs to DLN and activation of naïve T cells to become effector T 
cells. As a control peptide, β-Gal (H2Kb restricted) was used.  
To measure the immune response to the virus, serum samples were collected from all 
treated animals on 28th day following treatment. Further serum samples were 
measured for total anti-adenoviral antibody titers in the serum sample by ELISA. 
Interestingly, viroimmunotherapy with subsequent ovalbumin pulsed DC vaccination 
showed lower anti-adenoviral antibody titers (Figure 6.10) compared with MFT-MFT 
and DC-MFT treatment.  
 
These results indicate that viroimmunotherapy with subsequent ovalbumin pulsed DC 
vaccination is effective in generating an antigen-specific immune response and in 
reducing anti-adenoviral antibody titers. Tumor growth inhibition is also seen in the 
DBA/2 mice model. 
 
7.6 Generation of cytotoxic T cells by viroimmunotherapy  
 
We also considered that it is important to determine whether viroimmunotherapy had 
generated enough cytotoxic T cells (CTLs) to kill target cells. We performed an in 
vivo cytotoxicity assay after the following treatments. Mice were injected s.c. with 
CMT64-OVA cells. Tumors were treated with virotherapy or with 
viroimmunotherapy with or with out ovalbumin peptide pulsed DC vaccination, or 
first with ovalbumin peptide pulsed DC vaccination and subsequent 
viroimmunotherapy, or only ovalbumin pulsed DC vaccination. At day 28, mice were 
transferred i.v. with ova-peptide pulsed target cell with CFSEhi and control peptide 
with CFSElow labeled splenocytes. 
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As we expected, mice receiving viroimmunotherapy or viroimmunotherapy plus 
subsequent DC were able to kill OVA peptide pulsed CFSE labeled target cells more 
efficiently compared with controls or with those treated with virotherapy (hTERT) 
alone or DC vaccination alone (Figure 6.11a, b, c and d).  
 
Although DC vaccination alone and DC vaccination plus subsequent 
viroimmunotherapy caused cytotoxicity, the percentage of target cell killing is high 
after viroimmunotherapy with or without DC vaccination. Indeed, the cytotoxicity of 
viroimmunotherapy plus subsequent DC vaccination was lower than that after 
viroimmunotherapy alone; however, the cytotoxicity of MFT-MFT and MFT-DC 
treatments were more or less similar, but the anti-adenoviral antibody titers were 
lower in MFT-DC vaccination mice. This again shows the importance of 
viroimmunotherapy with subsequent antigen pulsed DC vaccination of poorly 
immunogenic carcinomas. 
 
7.7 Maturation and migration of DCs to lymph node play an 
important role in the activation of naïve T cells 
 
Localization in tissues and migration to lymphoid organs are essential steps in the 
immunobiology of DCs. Chemokines play an important role in guiding DC migration 
and regulating their maturation (Lin CL, 1998). In the present study, MIP-1α and 
Flt3L have been used as chemokines to attract DCs into the tumor bed. 
Among the antigen-presenting cells, DCs often acquire foreign antigens, and the 
maturation stimulated by inflammatory agonists causes rapid mobilization of DCs. 
Upon interaction of DCs with apoptotic tumor cells, CCR7 expression is induced, 
which further enhances the migration of mature DCs to DLNs (Hirao M, 2000). These 
mature DCs migrate to lymph nodes through lymphatic vessels and activate naïve T 
cells in DLN to become effector T cells (Randolph GJ, 2005). In our study, we have 
performed immunohistochemistry for MHC-II, CD80, and CD83 co-stimulatory 
molecules and FACS analysis of CD40 expression from tumor-infiltrating dendritic 
cells after treatment with MIP1α-Ad or Flt3L-Ad or a combination of them. The data 
indicates that these DCs exhibit high expression of CD40, MHC class-II, CD83, and 
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CD80 co-stimulatory molecules upon treatment (Figure 6.12a, 6.12b and 6.12c). 
Hence, these DCs are functionally active and efficiently migrate to the T cell zone of 
DLN. From the previous results concerning the immune response and cytotoxicity of 
target cells, this again confirms that these infiltrated DCs have matured, and migrated 
to DLN and activated naïve T cells to generate antigen-specific effector T cells. 
 
7.8 Viroimmunotherapy with subsequent tumor antigen loaded DC 
vaccination inhibits established lung metastasis 
 
Metastasis is the most lethal attribute of cancer cells, and clinical decisions regarding 
treatment are based largely upon the likelihood of the development of metastases 
(Danny R. Welch, 2006). When cancer survivor Clifton Leaf lamented the state of 
cancer research in early 2004, he concluded that progress in the “War on Cancer” was 
limited because research into the prevention and treatment of metastasis had been 
inadequate (Leaf C, 2004). He asserted that failure to control the establishment of 
secondary colonies was the major contributor to failure, and that winning against 
cancer would require increasing resources devoted to the study of metastasis.  
 
Some tumors are highly aggressive, forming secondary lesions with high frequency, 
such as small lung carcinoma and melanoma, whereas others are rarely metastatic, 
despite being locally invasive, for instance, basal cell carcinoma. Therefore, 
metastasis is not an inherent property of all invasive or neoplastic cells. Most 
secondary tumors arise from tumor cells migrating via the lymphatics (lymph node 
metastasis) and across body cavities.  
Hence, a study of the clinical relevance of viroimmunotherapy is important. In the 
present investigation, we used CMT64, a lung carcinoma cell line. This cell line 
causes aggressive tumors with an ability to cause distant metastasis.CMT64 cells were 
injected i.v. to establish lung metastasis followed by various regimes as follows: 
 
Control, virotherapy, viroimmunotherapy, and viroimmunotherapy with subsequent 
antigen pulsed DC vaccination. After two weeks of treatment, lungs were perfused 
with 3.7% formalin, fixed, embedded in paraffin, and prepared for light microscopy. 
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Discussion 
 
Deparaffinized sections were stained with hematoxylin-eosin according to a standard 
protocol. 
 
After viroimmunotherapy, lungs were identified with metastatic lesions in controls, 
and in animals treated with virotherapy alone, whereas viroimmunotherapy with or 
with out DC vaccination showed the inhibition of lung metastasis. Interestingly, 
viroimmunotherapy with subsequent DC vaccination showed very strong inhibition of 
lung metastasis and more than 50% of the cases of the animals cured lung metastasis 
(Figure 6.13a and 6.13b). Whether the adenovirus proteins migrated to the lungs and 
inhibited metastasis was not clear. We therefore performed immunohistochemistry of 
adenovirus hexon protein and ruled out the absence of the spreading of viral protein in 
lungs, except only in locally infected tumors (Figure 6.14). 
 
These results indicate the promising clinical relevance of viroimmunotherapy with 
subsequent DC vaccination, at least with regard to the inhibition of lung metastasis. 
 
7.9 Increased size of spleen and inhibition of tumor growth followed 
by viroimmunotherapy 
 
In addition to the inhibition of lung metastasis, we also observed that a significant 
delay occurred in the tumor growth of viroimmunotherapy treated mice compared 
with those in mice treated with control virus or virotherapy alone. Despite the delay of 
tumor growth after treatment with a combination of Ad-MIP-1α and Ad-Flt3L, a 
further combination of hTERT-Ad eradicated s.c. tumors (Figure 6.15). This can be 
explained by the replication of adenovirus in KLN205 tumor cells.  
 
Further, we observed that the treatment with viroimmunotherapy not only inhibited 
the tumor growth, but also increased size and number of splenocytes (Figure 6.16). 
These findings suggest that a combination of oncolytic virotherapy with 
immunotherapy is effective in curing tumor growth in more than 50% of animals and 
increasing spleen size. 
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 9 Abbreviations 
 
Ad      Adenovirus 
APC      Antigen presenting cells 
BMDC     Bone marrow dendritic cells 
CFSE      Carboxy Fluoroscein Succinimidyl Ester 
CTL      Cytotoxic T cells 
DC      Dendritic cells 
DMEM     Dulbecco´s Minimal Essential Medium 
ELISA      Enzyme-linked immunosorbent assay 
FCS      Fetal calf serum 
GrB      Granzyme B 
hTERT Human telomerase reverse transcriptase 
promoter 
IFN      Interferon 
IL      Interleukin 
i.v.      Intravenous 
i.p.      Intraperitoneal 
i.t      intratumoral 
lacZ      β-galactosidase gene 
Luc      Luciferase 
MHC      Major histocompatibility antigen 
MOI      Multiplicity of infection 
MFT      MIP-1α/Flt3L/hTERT-Ad 
NK      Natural killer cells 
NKT      Natural killer T cells  
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 PAMP      Pathogen-associated molecular patter 
PRR      Pattern recognition receptor 
Pfu      Plaque forming unit 
s.c      Subcutaneous 
TAA      Tumor-associated antigen 
TLR      Toll-like receptor 
TCR      T cell receptor 
TID      Tumor infiltrating dendritic cells 
TNFα      Tumor necrosis factor alpha 
VP      Viral particles 
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